Document:

EX-10.8

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS
BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 Exhibit
10.8 
 AGREEMENT 

This Agreement (this “Agreement”), dated and effective as of June 9, 2015 (“Effective Date”), is by and
between Coneksis, Inc. (“CONEKSIS”), a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133, and CONKWEST INCORPORATED (“CONKWEST”), a Delaware corporation
with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133. 
 PREAMBLE 

A. WHEREAS, CONKWEST is an innovative life sciences company that owns and/or controls the rights in certain CONKWEST Existing Rights (as
defined herein) and has the right to grant licenses thereto; 
 B. WHEREAS, CONEKSIS is an innovative life sciences company specializing in
the field of veterinary medicine and research and therapeutics related thereto (the “Field”); and 
 C. WHEREAS, CONEKSIS
desires to obtain rights to use certain of the CONKWEST Existing Rights in the Field, and CONKWEST desires to grant such certain rights to CONEKSIS, upon the terms and conditions hereinafter set forth. 

NOW THEREFORE, in consideration of the above premises and the mutual covenants contained herein, CONEKSIS and CONKWEST, intending to be
legally bound, agree as follows: 
 1. Definitions. For the purposes hereof, the following words and phrases have the following meanings: 

“AAA” has the meaning ascribed to it in Section 24. 

  
 -1- 

 “Biological Material” means a culture of any of the CONKWEST Cell Lines or
CONKWEST Cell Banks that is provided to CONEKSIS by CONKWEST pursuant to this Agreement and all Progeny thereof. 

“Claims” has the meaning ascribed to it in Section 9. 

“Commercial Product” means a Licensed Product that has been granted marketing and Regulatory Approval. 

“CONEKSIS Mark” means the trademark and/or service mark applied for in US Trademark Application No. 85/675,473, such
trade mark application and any registration resulting therefrom, any foreign or Madrid counterparts, any renewals thereof, and any goodwill associated therewith. 

“CONEKSIS Cell Bank(s)” means any GLP, cGMP, and/or GMP-certified CONEKSIS Cell Line(s). 

“CONEKSIS Cell Line(s)” means any modification or derivative of or improvement to a CONKWEST Cell Line resulting from a
CONEKSIS Modification. 
 “CONEKSIS Confidential Information” means all Confidential Information relating to the CONEKSIS
Cell Lines to the extent owned and controlled by CONKWEST. 
 “CONEKSIS Intellectual Property” means CONEKSIS Confidential
Information and CONEKSIS Patents pertaining to the CONEKSIS Modifications. 
 “CONEKSIS Modifications” has the meaning
ascribed to it in Section 2 and includes any and all CONEKSIS Intellectual Property, CONEKSIS Cell Line(s) and CONEKSIS Cell Bank(s) relating thereto. 

“CONEKSIS Option” has the meaning ascribed to it in Section 2. 

“CONEKSIS Patents” means any and all patents and patent applications to the extent owned and controlled by CONKWEST relating
to the CONEKSIS Modifications, and any provisional patent applications, non-provisional applications, divisionals, continuations, 

  
 -2- 

 
continuation-in-part applications, continued prosecution, patents granted on such applications, revalidations, reissues, renewals, substitutions, supplementary protection certificates and the
like, and patents of addition, reexaminations, extensions; and all foreign counterparts thereof. 
 “CONEKSIS Rights” means
the CONEKSIS Modifications and CONEKSIS Intellectual Property. 
 “Confidential Information” means all technical and other
information, data, methods, pricing information, inventions (whether patentable or not and whether or not reduced to practice), Know-How, INDs, investigator’s brochure(s) and other similar proprietary trade secret rights arising under law
anywhere in the world. 
 “CONKWEST Cell Banks” means the CONKWEST WT Master Cell Bank and the CONKWEST WT Working Cell
Bank. 
 “CONKWEST Cell Lines” means the CONKWEST CI Cell Line, the CONKWEST ER Cell Line, the CONKWEST MI Cell Line, and
the CONKWEST WT Cell Line. 
 “CONKWEST CI Cell Line” means the proprietary natural killer cell line transfected with the
pCEP4-LTRhIL-2 vector to express endogenous interleukin-2 and that is owned and controlled by CONKWEST as of the Effective Date. For clarity, CONKWEST CI Cell Line does not include any modifications, derivatives, or improvements thereof made by or
under the authority of CONKWEST or any Third Parties after the Effective Date. 
 “CONKWEST Confidential Information” means
all Confidential Information relating to the CONKWEST Cell Lines that is owned and controlled by CONKWEST. For clarity, CONKWEST Confidential Information expressly includes, but is not limited to, CONKWEST Know-How (including but not limited to
CONKWEST Investigator’s Brochure and CONKWEST IND(s)) and CONKWEST Report. 
 “CONKWEST ER Cell Line” means the
proprietary natural killer cell line transfected with the endoplasmic reticulum (ER) gene encoding the protein known as the KDEL motif and that is owned and controlled by CONKWEST as of the Effective Date. For clarity, CONKWEST ER Cell Line does not
include any modifications, derivatives, or improvements thereof made by or under the authority of CONKWEST or any Third Parties after the Effective Date. 

  
 -3- 

 “CONKWEST Existing Rights” means CONKWEST Cell Lines, CONKWEST Intellectual
Property, and CONKWEST Cell Banks. 
 “CONKWEST IND” means any IND owned and controlled by CONKWEST as of the Effective
Date that relates to the CONKWEST Cell Lines, including but not limited to US IND No. 8404 entitled “Investigational New Drug Application (IND) for Natural Killer Cell Line NK-92, Expanded with Interleukin-2” 

“CONKWEST Intellectual Property” means all CONKWEST Confidential Information and CONKWEST Patents pertaining to the CONKWEST
Cell Lines that are owned and controlled by CONKWEST as of the Effective Date, the CONKWEST Marks, and the Domain Name. 
 “CONKWEST
Investigator’s Brochure” means CONKWEST’s investigator brochure, version 12.0 dated September 1, 2012. 

“CONKWEST Know-How” means all Know-How pertaining to the CONKWEST Cell Lines that is owned and controlled by CONKWEST as of
the Effective Date, including that which is described on Schedule B hereto and Know-How pertaining to the CONKWEST Cell Lines incorporated into the CONKWEST IND(s) and CONWKEST Investigator’s Brochure. CONKWEST
Know-How does not include CONKWEST Patents. 
 “CONKWEST Marks” means those marks
listed on Schedule C hereto, which may be updated from time to time, owned and controlled by CONKWEST and any and all registrations and applications therefore in the United States and around the world. For clarity, the CONKWEST Marks include the
CONEKSIS Mark, unless and until CONEKSIS acquires such trademark pursuant to the CONEKSIS Option under Section 2(d) below. 

“CONKWEST MI Cell Line” means the proprietary natural killer cell line transfected with the MFG-hIL-2 vector to express
endogenous interleukin-2, and that is owned and controlled by CONKWEST as of the Effective Date. For clarity, CONKWEST MI Cell Line does not include any modifications, derivatives, or improvements thereof made by or under the authority of CONKWEST
or any Third Parties after the Effective Date. 

  
 -4- 

 “CONKWEST Patents” means the patents and patent applications owned and
controlled by CONKWEST that are listed on Schedule A hereto, which may be updated from time to time, and any provisional patent applications, non-provisional applications, divisionals, continuations, continuation-in-part applications, continued
prosecution, patents granted on such applications, revalidations, reissues, renewals, substitutions, supplementary protection certificates and the like, and patents of addition, reexaminations, extensions; and all foreign counterparts thereof. 

“CONKWEST Report” has the meaning ascribed to it in Section 2. 

“CONKWEST WT Cell Line” means the proprietary natural killer cell line known as the NK-92 wild type cell line, and that is
owned and controlled by CONKWEST as of the Effective Date. For clarity, the CONKWEST WT Cell Line does not include the CD16 expressing NK-92 cell line or any other modifications, derivatives, or improvements of the CONKWEST WT Cell Line made by or
under the authority of CONKWEST or any Third Parties after the Effective Date. 
 “CONKWEST WT Master Cell Bank” means the
GMP-certified CONKWEST WT Cell Line. CONKWEST Master Cell Bank does not include any modifications, derivatives, or improvements to the CONKWEST WT Cell Line made by or under the authority of CONKWEST or any Third Parties after the Effective Date.

 “CONKWEST WT Working Cell Bank” means the GLP and cGMP unmodified CONKWEST WT Cell Line. CONKWEST WT Working Cell Bank
does not include any modifications, derivatives, or improvements to the CONKWEST WT Cell Line made by or under the authority of CONKWEST or any Third Parties after the Effective Date. 

“Domain Name” has the meaning ascribed to it in Section 2. 

“Excluded Claim” has the meaning ascribed to it in Section 24. 

“FCCC Rights” has the meaning ascribed to it in Section 2. For clarity, any patents included in the FCCC Rights
controlled by CONKWEST are listed on Schedule D hereto, which 

  
 -5- 

 
may be updated from time to time, and any provisional patent applications, non-provisional applications, divisionals, continuations, continuation-in-part applications, continued prosecution,
patents granted on such applications, revalidations, reissues, renewals, substitutions, supplementary protection certificates and the like, and patents of addition, reexaminations, extensions; and all foreign counterparts thereof. 

“Field” has the meaning ascribed to it in the Preamble. 

“Force Majeure” means in relation to either Party, any event or circumstance (other than lack of funds) which is beyond the
reasonable control of that Party which event or circumstance that Party could not reasonably be expected to have taken into account at the date of this Agreement and which results in or causes the failure of that Party to perform any or all of its
obligations under this Agreement including, but not limited to, act of God, lightning, fire, storm, flood, earthquake, accumulation of snow or ice, lack of water arising from weather or environmental problems, strike, lockout or other industrial or
student disturbance, act of the public enemy, war declared or undeclared, threat of war, terrorist act, blockade, revolution, riot, insurrection, civil commotion, public demonstration, sabotage, act of vandalism, prevention from or hindrance in
obtaining in any way materials, energy or other supplies, explosion, fault or failure of plant or machinery (which could not have been prevented by good industry practice), or legal requirement governing either Party or acts, omissions or delays in
acting by any governmental authority. 
 “Gross Revenue” means gross receipts actually received by CONEKSIS or its
sublicensees from the Sale of a Commercial Product, Licensed Product, or Licensed Service, as the case may be. 
 “IND”
shall mean an Investigational New Drug Application, as defined in the United States Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or similar applications (i.e., a filing that must be made prior to commencing clinical
testing of a pharmaceutical product in human subjects) filed with an appropriate regulatory authority in any other jurisdiction. 

  
 -6- 

 “Indemnitees” means agents, directors, officers and employees of a Party
entitled to indemnification hereunder and their respective successors, assigns, administrators, executors and/or heirs. 

“Indemnitor” has the meaning ascribed to it in Section 9. 

“Innocent Party” has the meaning ascribed to it in Section 12. 

“Licensed Product” or “Licensed Service” means a product or service, as the case may be, which
(i) utilizes, utilized, or otherwise relies upon or relied upon, any or all of the CONKWEST Cell Lines and/or the CONKWEST Cell Banks or (ii) would, but for the licenses granted pursuant to Section 2(a)(ii) or Section 2(c)
hereto, infringe a Valid Claim. 
 “Non-Performing Party” has the meaning ascribed to it in Section 12. 

“Party” or “Parties” means CONKWEST, CONEKSIS, or both, depending on the context. 

“Person” or “person” means any corporation, partnership, limited liability company, joint venture, other
entity, or natural person. 
 “Progeny” means unmodified descendants from the Biological Material, such as virus from
virus, cell from cell or organism from organism. 
 “Quality Standards” means the quality levels which CONKWEST maintains
in connection with the CONKWEST Marks. 
 “Regulatory Approval” means, with respect to a state, nation or multinational
jurisdiction, (i) any approvals, licenses, registrations or authorizations necessary for the manufacture (where relevant), marketing and sale of a Licensed Product or Licensed Service in such state, nation or jurisdiction, and (ii) where
relevant, pricing approvals necessary to obtain reimbursement from a Government Authority. 
 “Results” has the meaning
ascribed to it in Section 6. 
 “Royalty” has the meaning ascribed to it in Section 5. 

  
 -7- 

 “Sale” means any transaction that transfers to an arm’s-length Third Party
purchaser, for value, title and right of physical possession to a Commercial Product, a Licensed Product, or a Licensed Service. Correspondingly, “Sell” means to make or cause to be made a Sale and “Sold” to have
made or caused to be made a Sale. 
 “Sublicensing Revenue” means any amounts received by CONEKSIS from a
non-Affiliated Third Party in consideration for the grant by CONEKSIS to such Third Party of (i) a sublicense under the CONKWEST Existing Rights and/or, if permitted, the FCCC Rights or (ii) the right to develop and/or commercialize any
Licensed Product(s), Licensed Service(s) and/or Commercial Product(s) (including but not limited to, the grant to veterinary specialty practices of exclusive rights to Sell Licensed Product(s), Licensed Services and/or Commercial Product(s), as
applicable, in particular geographic areas), including but not limited to any upfront payments, annual fees or maintenance payments, milestone payments or the like, but excluding: (a) amounts paid by such a Third Party as bona fide
reimbursement for research, development and/or other costs that CONEKSIS is obligated to incur in the performance of activities in accordance with such agreement, (b) bona fide loans, (c) amounts paid for supplies of product or other
tangible materials; and (d) royalties paid based on sales of Licensed Products, Licensed Services and/or Commercial Products; provided that CONEKSIS pays to CONKWEST any Royalties due to CONKWEST with respect thereto under
Section 5(a)(i) or (5(a)(ii) below, as applicable. 
 “Tax” means all charges, duties, fees, levies or other
assessments imposed by any tax authority, including but not limited to income, excise, property, sales, use, value added, profit, license, payroll, employment, net worth, capital gains, transfer, stamp, social security, environmental, occupation and
franchise taxes, and includes any interest, penalties and additions on these payments. 
 “Term” has the meaning ascribed
to it in Section 11. 
 “Third Party” means any Person other than CONKWEST or CONEKSIS. 

“Transfer” has the meaning ascribed to it in Section 2. 

  
 -8- 

 “Valid Claim” means a bona fide claim of any issued or pending CONKWEST Patent
or patent rights included in the FCCC Rights whose enforceability has not been affected by one or more of any of the following: (i) irretrievable lapse, expiration, revocation, cancellation or abandonment, and/or (ii) holding of
unenforceability or invalidity by a decision of a court or other appropriate body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and/or (iii) disclaimer or admission of invalidity or unenforceability
through reissue or re-examination or opposition, nullity action or invalidation suit response or otherwise. 
 “ZelleRx-FCCC
License” has the meaning ascribed to it in Section 2. 
 2. Grant of Rights. 

(a) Licenses to CONKWEST Rights. Subject to the terms and conditions of this Agreement, CONKWEST hereby grants to CONEKSIS, the
following rights and licenses for use solely in the Field: 
 (i) a perpetual, worldwide, exclusive license, with the limited right to
sublicense, under the following CONKWEST Existing Rights: (x) the CONKWEST Know-How, (y) the CONKWEST Cell Lines, and (z) the CONKWEST Cell Banks; 

(ii) a worldwide, exclusive license, with the limited right to sublicense, for the Term, under the CONKWEST Patents existing as of the
Effective Date; and 
 (iii) a perpetual, worldwide, exclusive, license, without right to sublicense, under the CONKWEST Marks; provided,
however that the license to the CONKWEST Marks is solely for the purpose of promoting, advertising, or marketing CONEKSIS products and/or CONEKSIS services, including but not limited to the Licensed Products, Licensed Services, and Commercial
Products, at the Quality Standards specified in Section 6 hereto; and further provided, however, that any and all use of the CONKWEST Marks in connection with the CONEKSIS products and/or services shall inure to the benefit of CONKWEST. 

The licenses granted in this Section 2(a) expressly exclude the right to reproduce, modify, publicly perform, publicly display, create derivative works
of, or otherwise create derivatives of or improvements to any of the CONKWEST Rights; provided, however, that, subject to the 

  
 -9- 

 
conditions set forth in the following subsections (I) to (III) and to Sections 2(b) and 3 hereto, CONEKSIS has the limited right to modify or otherwise create derivatives of or improvements
to the Biological Material and/or the CONKWEST Know-How (the “CONEKSIS Modifications”): 
 (I) if a given
CONEKSIS Modification may only be capable of use within the Field (i.e., is not relevant to human or non-human therapeutics) and CONEKSIS is making such CONEKSIS Modification internally, without any
collaboration or assistance of any sort from a Third Party, then such CONEKSIS Modification may be made without CONKWEST’s prior written approval; 

(II) if a given CONEKSIS Modification will or may be capable of use outside the Field in connection with human or non-human therapeutics, then such CONEKSIS Modification may be made only upon CONKWEST’s prior written approval, which approval shall not be unreasonably withheld; and 

(III) if CONEKSIS proposes to make any CONEKSIS Modification in collaboration, assisted by or otherwise with a Third Party, regardless of
whether such CONEKSIS Modification is capable of use outside the Field, whether in connection with human or non-human therapeutics or not, then such CONEKSIS Modification may be made only upon CONKWEST’s prior written approval, which approval
shall not be unreasonably withheld. Notwithstanding the foregoing, any CONEKSIS Modification made in collaboration, assisted by or otherwise with a Third Party, as well as all CONEKSIS Intellectual Property pertaining any such CONEKSIS Modification,
shall be at least jointly owned by CONEKSIS and CONEKSIS shall have the right to (and to authorize others, including CONKWEST and its Affiliates (other than CONEKSIS) to) use, practice, license, assign and/or otherwise exploit such CONEKSIS
Modification(s) and/or CONEKSIS Intellectual Property for any purpose without restriction and without the approval of or accounting to any such Third Party. 

The licenses granted to CONEKSIS by CONKWEST in this Section 2(a), together with the license granted to CONEKSIS by CONKWEST in Section 2(b) and the
sublicense granted to CONEKSIS by CONKWEST in Section 2(c), are collectively referred to as the “Licenses.” 

  
 -10- 

 (b) License to CONEKSIS Modifications. Subject to the terms and conditions of this
Agreement, and subject to Section 3 hereto, CONKWEST hereby grants to CONEKSIS a perpetual, worldwide, exclusive license solely for use in the Field, with the limited right to sublicense, under the CONEKSIS Rights. Notwithstanding the license
granted in Section 2(a)(i) hereto, CONKWEST hereby grants to CONEKSIS a perpetual, worldwide, limited exclusive license solely for use in the Field, with the limited right to sublicense, under the CONKWEST Cell Lines and the CONKWEST Know-How
existing as of the Effective Date, solely for use in conjunction with the CONEKSIS Modifications. 
 (c) Sublicense to FCCC Rights.

 (i) The Parties acknowledge that as of the Effective Date of this Agreement, CONKWEST and its Affiliates are the exclusive licensees
of certain intellectual property rights owned by Fox Chase Cancer Center (the “FCCC Rights”) pursuant to a certain exclusive license between ZelleRx Corporation (CONKWEST’s predecessor in interest) and Fox Chase Cancer Center
dated July 10, 2004 and amended on April 10, 2008 (the “ZelleRx-FCCC License”). The Parties also acknowledge and agree that as of the Effective Date of this Agreement, CONEKSIS is an affiliate (as that term is defined in
the ZelleRx-FCCC License) of CONKWEST and therefore also is an exclusive licensee of the FCCC Rights; provided that CONEKSIS covenants and agrees only to exercise its license under the FCCC Rights for uses within the Field. 

(ii) In addition, CONKWEST hereby grants to CONEKSIS, subject to the terms and conditions of this Agreement, an exclusive sublicense,
under the FCCC Rights, with a limited right to sublicense only to Affiliates of CONEKSIS or for the sole purpose of having licensed products (as that term is defined in ZelleRx-FCCC License) made for CONEKSIS, in each case, during the term of this
Agreement and solely for use in the Field; provided that CONEKSIS shall not exercise the sublicense granted to it under this Section 2(c)(ii) unless and until CONEKSIS ceases to be an affiliate (as that term is defined in the ZelleRx-FCCC
License) of CONKWEST. 
 (iii) Notwithstanding any other provision of this Section 2(c), in the event that the ZelleRx-FCCC License
terminates, such sublicense to the FCCC Rights shall 

  
 -11- 

 
automatically terminate effective ninety (90) days following termination thereof without the necessity of notice from FCCC regarding such termination, in which case the Parties acknowledge
that, in accordance with Section 2E of the ZelleRx-FCCC License, FCCC is obligated to negotiate in good faith for a period of ninety (90) days from such termination date to grant a license to CONEKSIS under the FCCC Rights. In addition,
CONEKSIS acknowledges and agrees that CONEKSIS’ exercise of the license under the FCCC Rights as an affiliate of CONKWEST (as described in Section 2(c)(i) above) or as a sublicensee of CONKWEST (as described in Section 2(c)(ii) above)
shall, in all cases, be subject to the terms of the ZelleRx-FCCC License (as such agreement may be amended from time to time after the Effective Date) and CONEKSIS agrees to comply, and shall comply, in the exercise of its (sub)license under the
FCCC Rights with all terms and conditions of the ZelleRx-FCCC License applicable to an affiliate or sublicensee of CONKWEST, as the case may be, as if such terms of the ZelleRx-FCCC License were incorporated herein by reference, including without
limitation, the following provisions of the ZelleRx-FCCC License: Sections 2D, 2E, 3F, 6B, 6C, 7B, 10A and 10G. 
 (d) Option to the
CONEKSIS Mark. Subject to the terms and conditions of this Agreement, CONKWEST hereby grants to CONEKSIS, during the term of this Agreement, a first option to acquire the CONEKSIS Mark, including applications and registrations therefor in the US
and abroad, together with the goodwill of the business symbolized by the CONEKSIS Mark (the “CONEKSIS Option”), the terms of such acquisition to be reasonably negotiated by the Parties within a reasonable time of CONEKSIS exercising
such CONEKSIS Option. 
 (e) Transfer of Domain Name. CONKWEST hereby transfers (the “Transfer”) to CONEKSIS all of
its rights, title, and interest in and to the domain name “www.coneksis.com” (the “Domain Name”) and shall, within thirty (30) days of the Effective Date of this Agreement, effectuate such transfer with the registrar
of the Domain Name. 
 (f) Sublicense Rights. For purposes of clarity, CONEKSIS is entitled to sublicense the rights granted in
Sections 2(a)(i), 2(a)(ii), 2(b), and 2(c) hereto (including the right to distribute the Biological Material) only for use in the Field and to the extent necessary to develop and/or commercialize Commercial Product(s), Licensed Product(s) and/or
Licensed Services, as 

  
 -12- 

 
the case may be; provided, however, that (i) such sublicensee(s) shall not be authorized to grant any further sublicense; (ii) any sublicenses granted by CONEKSIS under the FCCC Rights
shall be in accordance with Section 2(c) above and the ZelleRx-FCCC License; and (iii) to the extent any such sublicenses may involve the creation of any CONEKSIS Modification, CONKWEST’s prior written approval thereto must be
obtained in accordance with Section 2(a) above. Any sublicenses granted by CONEKSIS under the terms of this Agreement shall be subject to terms and conditions that are at least as restrictive as those set forth in this Agreement. CONEKSIS shall
notify CONKWEST of any sublicense granted by CONEKSIS relating to this Agreement with thirty (30) days thereafter and upon CONKWEST’s request shall provide to CONKWEST a copy of any such sublicense agreement, which copy may be redacted to
remove any terms not reasonably required for the purposes of determining compliance with the terms of this Agreement. For clarity, CONEKSIS does not have the right to sublicense the rights granted in Section 2(a)(iii) hereto. 

(g) Licensee and Sublicensee Compliance. CONEKSIS will, and will undertake that its Affiliates and sublicensees will, comply with all
laws, rules, regulations and guidelines which apply to the use of the Biological Material, the CONKWEST Know-How, and the CONKWEST Patents, including without limitation, those promulgated by the U.S. Food and Drug Administration (or the foreign
local equivalent), and those relating to the export and import of the Biological Material and the CONKWEST Know-How. 
 (h) Transfer of
Biological Material and Know-How. CONKWEST shall provide the Biological Material to CONEKSIS, without charge for handling and delivery therefore, on a date mutually agreeable to both Parties and pursuant to reasonable delivery instructions
provided by CONEKSIS to CONKWEST in advance. CONKWEST shall also provide CONEKSIS a report (the “CONKWEST Report”) containing CONKWEST Know-How, including instructions on how to work with the Biological Material, no later than the
time of the provision of the Biological Material. The CONKWEST Report shall be regarded at all times as CONKWEST Confidential Information. 

(i) Sharing of CONKWEST IND(s). CONKWEST shall permit CONEKSIS to access, and shall provide CONEKSIS sufficient rights to reference and
use in association with 

  
 -13- 

 
CONEKSIS exercising its rights and performing its obligations under this Agreement, the CONKWEST IND(s) and regulatory communications associated with any submissions of such CONKWEST IND(s). For
the avoidance of doubt, CONEKSIS shall exercise such rights of reference and use provided by CONKWEST to CONEKSIS under this Section 2(i) solely with respect to Licensed Products, Licensed Services and/or Commerical Products within the Field.

 3. Ownership; Prosecution/Maintenance; Reservation of Rights; No Additional Rights. 

(a) Ownership of CONKWEST Existing Rights. CONEKSIS acknowledges that subject to the licenses or sublicenses, as the case may be,
granted to CONEKSIS by CONKWEST in Sections 2(a) and 2(c) hereunder, all right, title and interest in and to the CONKWEST Existing Rights is and shall remain the sole property of CONKWEST. CONEKSIS further acknowledges and agrees that, except as
expressly permitted in Section 2(a) hereto, it shall not modify or improve the CONKWEST Existing Rights without the prior written consent of CONKWEST, nor use the CONKWEST Existing Rights for any purpose outside of the Field. 

(b) Ownership of CONEKSIS Modifications. CONEKSIS and CONKWEST agree that ownership and inventorship with respect to any Intellectual
Property developed hereunder shall be determined according to US laws; provided, however, that subject to the license granted to CONEKSIS by CONKWEST under Section 2(b) hereto, all right, title, and interest in and to the CONEKSIS Modifications
is and shall remain the sole property of CONKWEST and, to the extent such CONEKSIS Modifications are identified, discovered, invented, acquired, and/or developed by CONEKSIS (by itself or in collaboration with Third Party(ies)), CONEKSIS hereby
assigns, and/or shall cause to be assigned, to CONKWEST all of its right, title, and interest in and to such CONEKSIS Modifications. 
 (c)
Prosecution/Maintenance. The Parties shall reasonably cooperate with each other in preparing and filing all appropriate documentation in connection with any patent applications 

  
 -14- 

 
or patents under this Section 3(c). Subject to the terms and conditions of any agreement(s) with a Third Party regarding the CONEKSIS Modifications: 

(i) CONKWEST shall consult with CONEKSIS to determine in which countries any patent applications related to any CONEKSIS
Modifications shall be filed, prosecuted, and maintained, including corresponding PCT applications and national phase entry applications, and any and all patent applications, prosecution, issue and maintenance fees related to any divisional,
substitute, reissue, continuation, or extension patents that are based thereon; 
 (ii) Unless otherwise agreed in writing,
CONKWEST shall pay for any and all fees and costs resulting from drafting, filing, prosecuting, or maintaining such patents or patent applications related to such CONEKSIS Modifications and shall keep CONEKSIS reasonably informed on the status of
such patents and patent applications; and 
 (iii) In the event that CONKWEST decides not to file a patent or patent
application described under Section 3(c)(i) hereto, or decides not to prosecute or maintain any such patent application or patent under Section 3(c)(ii) hereto, then CONEKSIS shall have the right, but not the obligation, to file,
prosecute, or maintain such patent application or patent, in which case CONEKSIS shall bear all costs and expenses related thereto, beginning on the date that CONEKSIS exercises such right and CONEKSIS shall keep CONKWEST reasonably informed on the
status of any such patents and/or patent applications. 
 (iv) Each Party shall cooperate with the other Party in
connection with activities relating to the preparation, filing, prosecution and maintenance of patents and patent applications relating to the CONEKSIS Modifications undertaken by the other Party pursuant to this Section 3(c), including:
(A) making available to such other Party in a timely manner any documents or information reasonably necessary or appropriate to facilitate such other Party’s filing, prosecution and maintenance of any such patent or patent application; and
(ii) if and as appropriate, signing (or causing to have signed) all documents relating to the filing, prosecution and maintenance of any such patent or patent application by such other Party. Each Party shall also promptly provide to the other
Party all information reasonably requested by such other Party with regard to such Party’s activities pursuant to this Section 3(c). 

  
 -15- 

 (d) Ownership of Results. Notwithstanding Sections 3(a) and 3(b) hereto, all right, title,
and interest in and to any results and data arising in any part of the world developed by or under the authority of CONEKSIS (by itself or in collaboration with or with the assistance of any Third Party) as a result of its use of any or all of the
CONKWEST Existing Rights or the CONEKSIS Modifications (collectively, “Results”) shall, as between the Parties, be the exclusive property of CONEKSIS and, subject to Section 3(e) hereto, CONKWEST shall have no rights therein.
CONEKSIS shall have the unrestricted right to publish or otherwise disclose Results obtained by the practice of the rights granted under this Agreement provided such disclosure does not include any CONKWEST Confidential Information. The name of
CONKWEST shall be given proper recognition in such publication(s) as scientifically appropriate. 
 (e) License to Results.
Notwithstanding Section 3(d), CONEKSIS shall provide CONKWEST with a copy of any new Results generated by or under the authority of CONEKSIS on a reasonably regular basis during the TERM (but in no event less than once every six (6) months
or as otherwise reasonably requested by CONKWEST). CONEKSIS hereby grants CONKWEST a non-exclusive, perpetual, irrevocable, royalty-free, license to use the Results solely for CONKWEST’s internal research purposes and outside the Field.
Notwithstanding the foregoing, it is understood that the license granted by CONEKSIS to CONKWEST in this Section 3(e) shall include the right for CONKWEST to authorize a third party conducting research and/or other activities for or on behalf
of CONKWEST outside the Field to use any Results in the performance of such activities . For clarity, such Results shall be considered to be CONEKSIS’ proprietary and Confidential Information. Except as specified in this Section 3(e),
CONKWEST is expressly prohibited from disclosing such Results to Third Parties and, to the extent such Results are provided in tangible form, CONKWEST shall not create derivative works thereof or, except for its own internal research purposes,
reproduce, display, distribute, or perform such Results. 
 (f) Reservation of Rights; No Additional Rights. All rights not
specifically granted to CONEKSIS herein are expressly reserved by CONKWEST. For the avoidance of doubt, except as expressly set forth in Section 2(a) hereto, CONEKSIS is expressly prohibited from reproducing, modifying, publicly performing,
publicly displaying, creating derivative works of, 

  
 -16- 

 
or otherwise creating derivatives of or improvements to any of the CONKWEST Existing Rights or the Biological Material and from Selling, transferring, assigning, or otherwise providing any Third
Party access to the CONKWEST Existing Rights or the Biological Material. Nothing contained herein shall be construed to confer any rights upon either Party by implication, estoppel, or otherwise as to any technology or patent rights of the other
Party other than those which are expressly set forth herein. 
 4. Manufacture of Licensed Products. CONKWEST shall have the first
right, but not the obligation, to manufacture Licensed Products and/or Commercial Products for CONEKSIS, whereby, for each order of Licensed Products, CONKWEST shall notify CONEKSIS in writing within thirty (30) days of CONKWEST’s receipt
of an order of its decision to manufacture such Licensed Products or not; provided, however, that CONEKSIS may engage a Third Party to manufacture Licensed Products in the event that CONKWEST is unable or unwilling to manufacture and deliver such
Licensed Products in the timeframe and/or quantity required by CONEKSIS and at a price agreeable to the Parties, such pricing to be reasonably negotiated. 

5. Consideration; Payment. 

(a) Royalty Payments. In consideration of the Licenses granted in Section 2 hereto, CONEKSIS agrees to pay CONKWEST during the
TERM: 
  

	 	(i)	a “Royalty” or “Royalties” for the Licensed Products and/or Licensed Services Sold, distributed, or otherwise transferred by CONEKSIS and/or its sublicensees, in the amount of three
percent (3%) of the Gross Revenue actually received by CONEKSIS and/or its sublicensees therefor; 

  

	 	(ii)	a “Royalty” or “Royalties” for the Sale of Commercial Products by CONEKSIS and/or its sublicensees in the amount of three percent (3%) of the Gross Revenue actually received by
CONEKSIS and/or its sublicensees therefor; and/or 

  

	 	(iii)	CONEKSIS shall pay CONKWEST five percent (5%) of any Sublicensing Revenue actually received by CONEKSIS. 

  
 -17- 

	 	(iv)	All amounts necessary to reimburse CONKWEST for amounts payable by CONKWEST under the ZelleRx-FCCC License as a result of or arising from CONEKSIS’ exercise of the rights granted to it under the FCCC Rights
pursuant to this Agreement. 

 CONEKSIS (itself or by or through its permitted sublicensees and/or other contractors) shall take all
commercially reasonable steps to develop, commercialize, and promote the sales of Licensed Products, Licensed Services and/or Commercial Products. CONEKSIS will have no obligation to pay CONKWEST a “Minimum Annual Royalty” on any
Commercial Products, Licensed Products or Licensed Services. 
 All Royalties and other amounts due pursuant to this Section 5(b) for a particular
calendar quarter shall be due and payable by CONEKSIS to CONKWEST in U.S. dollars within thirty (30) days following the end of such calendar quarter. With each payment, CONEKSIS shall provide a written statement setting forth the total Gross
Revenue and Sublicensing Revenues for the applicable calendar quarter and such other information as CONKWEST may reasonably request in order to verify the calculation of payments made by CONEKSIS to CONKWEST under this Agreement or to satisfy
CONKWEST’s reporting obligations under the ZelleRx-FCCC License. 
 (c) Method of
Payment. All payments to CONKWEST hereunder shall be made payable to CONKWEST and sent to the address identified in Section 13 or remitted to CONKWEST’s account at a bank in the United States to be designated by CONKWEST in writing and
sent to CONEKSIS in advance of such payment. 
 (d) Third-Party Payments. Subject to Section 5(a)(iv) above, CONKWEST is
responsible for all payments, if any, to Third Parties that are owed pursuant to any agreement executed by CONKWEST prior to the Effective Date as a result of CONEKSIS exercising the Licenses granted by CONKWEST to CONEKSIS herein in accordance with
the terms and conditions of this Agreement. Notwithstanding the foregoing, CONEKSIS is responsible for obtaining, at its expense, any Third Party intellectual property required to utilize, practice or otherwise perform under the Licenses granted
herein, including the development and commercialization of its products, including the Commercial Products, Licensed Products and/or Licensed Services. 

  
 -18- 

 (e) Payments in U.S. Dollars. All payments due hereunder are payable in United States
dollars. 
 (f) Taxes: 

(i) All payments due hereunder are inclusive of all applicable Taxes subject however to Section 3(f)(ii) below. If any
such Taxes are chargeable in respect of any payments, CONEKSIS shall pay such Taxes at the applicable rate in respect of any such payments following the receipt, where applicable, of a Taxes invoice in the appropriate form issued by CONKWEST in
respect of those payments. The applicable Taxes shall be payable on the due date of the payment to which such Taxes relate. 

(ii) CONEKSIS may deduct withholding Taxes from the payment it owes CONKWEST under this Agreement. CONEKSIS will, on behalf of
CONKWEST, pay the withheld Tax to the appropriate authority and provide CONKWEST with proof of payment and evidence of the tax obligation. CONEKSIS will at CONKWEST’s request and expense provide CONKWEST reasonable assistance in recovering
these withholding Taxes. 
 (g) Maintenance of Records. CONEKSIS shall keep accurate records of all of its operations and of reports
of operations by its sublicensees within the scope of this Agreement. CONKWEST, at its sole expense, shall have the right to have a Certified Public Accountant of its choice inspect such records at CONEKSIS’ office for two years after the
calendar year to which they pertain at reasonable times upon two (2) weeks prior written notice by CONKWEST. In addition, and without limiting the foregoing, CONEKSIS shall comply with the record keeping and auditing requirements of the
ZelleRx-FCCC License, as communicated by CONKWEST to CONEKSIS reasonably in advance. 

  
 -19- 

 6. Quality Standards. 

(a) In order to carry out the rights granted in Section 2(a)(iii) hereto, CONEKSIS is authorized to use the CONKWEST Marks in such style,
appearance and manner as CONKWEST shall, in its sole discretion, specify or approve in writing and solely on or in association with products and/or services in the Field and in strict accordance with all of the applicable Quality Standards. CONEKSIS
may not manufacture, sell, promote, or distribute any product or service to be used in association with the CONKWEST Marks, including but not limited to the Licensed Products and Licensed Services, until it has obtained the requisite written
approvals from CONKWEST. It is within CONKWEST’s sole reasonable discretion to grant or withhold any approval. CONEKSIS further understands that it is an essential condition of the validity of this Agreement, of the validity of the CONKWEST
Marks licensed herein, and for the protection of the high reputation enjoyed by CONKWEST, that the products and services produced in association with any of the CONKWEST Marks be of high and consistent quality subject to the on-going approval and
continuing supervision and control of CONKWEST. 
 (b) CONEKSIS is expressly prohibited from modifying the CONKWEST Marks unless expressly
agreed to and such modifications are expressly approved in writing by CONKWEST. 
 (c) CONEKSIS will not use the CONKWEST Marks in
conjunction or association with any other trademark, trade name, or logo, or place the CONKWEST Marks in close proximity to any other name, mark or logo without the express prior written approval of CONKWEST. 

(d) CONEKSIS will comply as soon as reasonably practicable (but in any event within twenty days) with all reasonable instructions furnished by
CONKWEST from time-to-time with respect to the style, appearance and manner of use of the CONKWEST Marks on or in connection with the products and/or services, including instructions to revise the style, appearance or manner of use as CONKWEST may
specify from time to time. 
 (e) Whenever the CONKWEST Marks are used on or in connection with the products and/or services, CONEKSIS shall
use the trademark symbol “TM”, the service mark symbol “SM”, or the registration symbol “®”, as appropriate. 

  
 -20- 

 7. Infringement by Third Parties. 

(a) Notice. If any of the CONKWEST Existing Rights or the CONEKSIS Modifications are infringed and/or misappropriated by a Third Party,
the Party first having knowledge of such infringement and/or misappropriation shall promptly notify the other Party in writing. The notice shall set forth the facts of such infringement and/or misappropriation in reasonable detail. 

(b) Infringement Actions; CONKWEST Rights/CONEKSIS Modifications. CONKWEST shall have the sole and exclusive right, but not the
obligation, to institute, litigate and control any claim, action or proceeding with respect to any infringement and/or misappropriation by a Third Party (an “Infringement Action”) of any of the CONKWEST Existing Rights or the CONEKSIS
Modifications, by counsel of its own choice, in which case CONEKSIS shall reasonably cooperate with CONKWEST at CONKWEST’s request and expense in the litigation of such Infringement Action; provided, however, that CONEKSIS shall not be
obligated to join in any such Infringement Action related to the CONKWEST Existing Rights or the CONEKSIS Modifications (subject to ownership of the CONEKSIS Modifications) except to the extent necessary for standing purposes. CONKWEST shall be
entitled to make all decisions with respect to control of litigation, settlement, consent judgment or other voluntary final disposition of an Infringement Action regarding the CONKWEST Existing Rights and/or the CONEKSIS Modifications; provided that
CONKWEST shall have no right or authority to bind CONEKSIS with respect to any such matters without CONEKSIS’ express prior written consent; and provided, however, that CONKWEST’s rights and obligations under this Section 7(b) with
respect to the CONEKSIS Modifications are subject to the terms and conditions of any agreement(s) with a Third Party with whom CONEKSIS collaborated to identify, discover, invent, acquire, and/or develop such CONEKSIS Modifications. 

8. Representations and Warranties. 
 (a)
Each Party hereby represents and warrants to the other Party as of the Effective Date that: 
 (i) it is a corporation duly
organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated; 

  
 -21- 

 (ii) it has the corporate power and authority and the legal right to enter into
this Agreement free from any conflicting right owed to a Third Party and to perform its obligations hereunder; 
 (iii) it
has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder and that this Agreement has been duly executed and delivered on behalf of each Party, and
constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms; 
 (iv) all
necessary consents, approvals and authorizations of all applicable competent authorities and other persons required to be obtained by such Party in order to execute this Agreement on behalf of such Party have been obtained; and 

(v) the execution and delivery of this Agreement and the performance of such Party’s obligations do not constitute a
default or require any consent under any other contractual obligation of such Party. 
 (b) CONKWEST hereby represents and warrants to
CONEKSIS that as of the Effective Date: 
 (i) CONKWEST owns and controls within the Field the CONKWEST Existing Rights, and
has obtained all necessary assignments, licenses, and other rights in and to the CONKWEST Existing Rights necessary to provide to CONEKSIS the Biological Material and CONKWEST Know-How and grant the Licenses as described herein; 

(ii) CONKWEST has the sole and exclusive right to grant to CONEKSIS the Licenses, Option, and Transfer set out in this
Agreement; and 
 (iii) CONKWEST has not previously entered into any agreement, whether written or oral, with respect to the
CONKWEST Existing Rights which conflicts with the rights granted to CONEKSIS hereunder and will not enter into any such agreement during the Term of this Agreement. 

  
 -22- 

 (c) CONEKSIS hereby represents and warrants to CONKWEST that: 

(i) CONEKSIS will not attend any meetings with regulatory agencies that relate to the CONKWEST Existing Rights unless it is
accompanied by a representative of CONKWEST or CONKWEST agrees in writing that CONEKSIS may attend such meetings in the absence of CONKWEST; 

(ii) CONEKSIS shall not, and shall not collude with, authorize or assist any Third Party to, use any of the CONKWEST Existing
Rights or any of the CONEKSIS Modifications outside of the Field; 
 (iii) CONEKSIS shall not, and shall not collude with,
authorize or assist any Third Party to, take any action to intentionally compete, directly or indirectly, with CONKWEST outside of the Field; and 

(iv) CONEKSIS shall not, and shall not collude with, authorize or assist any Third Party to, distort, misuse, diminish,
infringe, dilute, contest or challenge CONKWEST’s rights in and to, ownership of, and registrations or applications for registration of, CONKWEST’s Existing Rights or the CONEKSIS Modifications. 

9. Indemnification. 
 (a)
CONKWEST shall indemnify, defend and hold harmless CONEKSIS and its Indemnitees from and against any and all claims, losses, demands, liabilities, judgments, actions, causes of action, costs and expenses, of any type or kind (including reasonable
attorneys’ fees) (collectively “Claims”) brought by a Third Party, if the Claims: 
 (i) result from a
breach of CONKWEST’s representations and warranties under Section 8 hereinabove; 
 (ii) result from a material
breach by CONKWEST of the terms of this Agreement; or 

  
 -23- 

 (iii) result from a claim that the CONKWEST Existing Rights infringe the
intellectual property of a Third Party; 
 provided, however, that CONKWEST shall not be obligated to indemnify CONEKSIS and its Indemnitees
under this Section 9(a) to the extent the Claims are a result of negligence or willful misconduct of CONEKSIS or its Indemnitees or a matter with respect to which CONEKSIS is obligated to indemnify CONKWEST pursuant to Section 9(b)
below, and provided further, that CONKWEST’s liability to indemnify CONEKSIS or its indemnities under this Section 9(a) shall not exceed the amounts paid by CONEKSIS to CONKWEST hereunder. 

(b) CONEKSIS shall indemnify, defend and hold harmless CONKWEST and its Indemnitees from and against any and all Claims brought by a Third
Party, if the Claims: 
 (i) result from a breach of CONEKSIS’ representations and warranties under Section 8 hereinabove; 

(ii) result from the material breach by CONEKSIS of the terms of this Agreement or any terms of the ZelleRx-FCCC License
applicable to CONEKSIS in its capacity as an affiliate (as defined in the ZelleRx-FCCC License) of CONKWEST or CONKWEST’s sublicensee; 

(iii) result from the development, commercialization, Sale, distribution or use of a Licensed Product, Licensed Service, and/or
Commercial Product by or under the authority of CONEKSIS or its sublicensees; 
 (iv) result from any use of the Biological
Material or CONKWEST Know-How by CONEKSIS or its sublicensees (other than claims that the CONKWEST Cell Lines infringe the intellectual property rights of a Third Party); or 

(v) result from a claim that the CONEKSIS Modifications infringe the intellectual property of a Third Party; 

provided, however, that CONEKSIS shall not be obligated to indemnify CONKWEST and its Indemnities under this Section 9(b) to
the extent the Claims are a result of negligence or willful misconduct of CONKWEST or its Indemnitees or a matter in respect of which CONKWEST is obligated to indemnify CONEKSIS pursuant to Section 9(a) above. 

  
 -24- 

 (c) In order to maintain the right to be covered under Section 9(a) or (b), the Indemnitee
must: (i) promptly notify the indemnifying Party (“Indemnitor”) in writing after learning of any Claims; (ii) allow the Indemnitor to manage and control (by way of intervention or otherwise) the defense and settlement of
any such Claims against the Indemnitees; (iii) cooperate with the Indemnitor in the defense or the settlement negotiation of Claims reasonably required by the Indemnitor; and (iv) abstain from making any statements or taking any actions
which damage the defense against any Claims (including, without limitation, any statements against the interest of the Indemnitees or admissions of causation or guilt). The Indemnitor shall not agree to any settlement that adversely affects the
Indemnitees’ rights or interests without the Indemnitees’ prior written approval (which approval shall not be unreasonably withheld). The Indemnitor will not be responsible for any costs or expenses (including attorney fees) incurred or
made by the Indemnitees without Indemnitor’s prior written consent, and then only to the extent they are reasonable. The Indemnitees may retain its or their own legal counsel to monitor an indemnification event, but the Indemnitees shall be
responsible for its own costs and expenses with respect thereto, subject to the preceding sentence. 
 (d) Disclaimer of Warranties.
EXCEPT AS SPECIFICALLY STATED IN SECTION 8 ABOVE, CONKWEST MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. WARRANTIES DISCLAIMED INCLUDE, BUT ARE NOT LIMITED TO, ANY EXPRESS OR IMPLIED WARRANTIES OF DESIGN,
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICE. 
 (e) Limitations of
Liability. IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY LOST REVENUES, LOST PROFITS, OR OTHER INCIDENTAL, SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR ITS PERFORMANCE OR BREACH, EVEN IF THEY HAVE BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT THE FOREGOING LIMITATION 

  
 -25- 

 
OF LIABILITY SHALL NOT APPLY TO LIMIT A PARTY’S DAMAGES IN THE EVENT OF (A) THE OTHER PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER SECTION 10 BELOW, (B) THE USE BY
OR UNDER THE AUTHORITY OF CONEKSIS OF ANY OF THE CONKWEST EXISTING RIGHTS OR CONEKSIS MODIFICATIONS OUTSIDE IN THE FIELD IN BREACH OF THIS AGREEMENT OR (C) ANY BREACH BY CONEKSIS OF SECTION 2(c) ABOVE. FOR THE AVOIDANCE OF DOUBT, DIRECT
FINANCIAL OR OTHER LOSSES, INCLUDING LOSSES RESULTING FROM CONEKSIS’ BREACH OF THE SCOPE OF THE LICENSES, ARE EXCLUDED FROM THIS PROVISION. 

(f) The provisions of this Section shall survive termination. 

10. Confidentiality. 
 (a) Each Party,
with respect to the other Party’s Confidential Information: 
 (i) may only use the Confidential Information for the
purposes envisaged under this Agreement; 
 (ii) must ensure that only those of its officers, employees, sublicensees and
Third Parties working with, for and/or on behalf of such Party who are directly concerned with carrying out the purposes envisaged under this Agreement have access to the Confidential Information on a strictly applied “need to know” basis,
are informed of the secret and confidential nature of it, and have entered into written agreements, prior to such disclosure, obligating them to hold in confidence and not use any Confidential Information except as permitted by this Agreement; 

(iii) must keep the Confidential Information secret and confidential and not disclose or permit to be disclosed, make available
or permit to be made available the same to any Third Party for any reason without the prior written consent of the disclosing Party or except as set forth in this Agreement; and 

(iv) must not copy, reproduce or otherwise replicate for any purpose or in any manner whatsoever any documents containing the
Confidential Information except as necessary to exercise the rights granted it and/or in the performance of its obligations under this Agreement. 

  
 -26- 

 (b) The obligations of confidence referred to in Section 10(a) shall not extend to any
Confidential Information which: 
 (i) is or becomes generally available to the public otherwise than by reason of breach by
a recipient Party of the provisions of this Agreement; 
 (ii) is known to the recipient Party and is at its free disposal
prior to its receipt from the disclosing Party provided that evidence of such knowledge is proven by competent written records; 

(iii) is subsequently disclosed to the recipient Party without obligations of confidence by a Third Party owing no such
obligations to the disclosing Party in respect of that Confidential Information; 
 (iv) is independently developed by a
Party without reliance on the Confidential Information of the other Party, provided that evidence of such is proven by competent written records; or 

(v) is required to be disclosed in order to comply with any law, regulation or valid court order (including, without
limitation, as part of any regulatory submission or approval process) to the extent necessary for such compliance; provided, however, the Party seeking such disclosure shall provide prompt written notice of this requirement to the disclosing Party
in order to provide the disclosing Party an opportunity to seek appropriate relief to prevent or limit such disclosure, provided always that in such circumstances such disclosure shall be only to the extent so required and shall be subject to
reasonable prior consultation with the disclosing Party with a view to agreeing to the timing and content of such disclosure, or other such equitable relief and shall reasonably cooperate with such other Party’s efforts to seek confidential
treatment of any Confidential Information to be disclosed. 

  
 -27- 

 (c) All Confidential Information owned by and disclosed by the disclosing Party to the recipient
Party shall remain the property of the disclosing Party. In the event that a court or competent authority assumes partial or complete control over the assets of a recipient Party based on the insolvency or bankruptcy of that Party, the recipient
Party shall promptly notify such court or competent authority that (i) Confidential Information received from the disclosing Party under this Agreement remains the property of the disclosing Party; and (ii) of the confidential obligations
under this Agreement; and to the extent permitted by law, take all steps reasonably necessary to maintain the confidentiality and security of the disclosing Party’s Confidential Information to ensure that the court or competent authority
maintains that Confidential Information in confidence in accordance with this Agreement. 
 (d) The obligations of the Parties under
Section 10 shall last until the Confidential Information is no longer secret and confidential through no breach of any provision of this Agreement. 

(e) The requirement under Section 10(b)(v) to notify the disclosing Party when Confidential Information is required to be disclosed by
law shall not apply when such disclosure is required as part of any regulatory submission or approval process. 
 (f) Each Party agrees not
to disclose to any Third Party the terms of this Agreement without the prior written consent of the other Party hereto, except each Party may disclose the terms of this Agreement: (i) to advisors (including financial advisors, attorneys and
accountants), actual or potential sublicensees, acquisition partners or investors, and others on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those in this Agreement; or (ii) to the
extent necessary to comply with applicable laws and court orders, including securities laws, regulations or guidances; provided that in the case of paragraph (ii) the disclosing Party shall promptly notify the other Party and (other than in the
case where such disclosure is reasonably necessary to comply with securities laws, regulations or guidances) allow the other Party a reasonable opportunity to oppose with the body initiating the process and, to the extent allowable by law, to seek
limitations on the portion of the Agreement that is required to be disclosed. 

  
 -28- 

 11. Term; Termination. 

(a) This Agreement shall come into force on the Effective Date and: 

(i) with respect to the licenses granted in Sections 2(a)(i), 2(a)(iii), and 2(b) shall remain in full force and effect
perpetually, unless terminated as herein provided; 
 (ii) with respect to the license granted in Section 2(a)(ii),
shall remain in full force and effect, unless earlier terminated as herein provided, until the last-to-expire Valid Claim (the “Term”), at which time such license shall be fully paid up and perpetual, unless terminated as herein
provided; and 
 (iii) with respect to the sublicense granted in Section 2(c) shall remain in full
force and effect for as long as the ZelleRx-FCCC License remains in full force and effect. 
 (b)
Termination for Insolvency. 
 (i) If voluntary or involuntary proceedings by or against a Party are instituted in
bankruptcy under any insolvency law, or a receiver or custodian is appointed for such Party, or proceedings are instituted by or against such Party, in each of the foregoing cases only if it is for dissolution of such Party, which proceedings, if
involuntary, shall not have been dismissed within sixty (60) days after the date of filing, then this Agreement may be terminated by the other Party. 

(ii) Notwithstanding Section 3(b), all rights and licenses granted under this Agreement are, and shall be deemed to be,
for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the United States Bankruptcy Code. In the event of the commencement of a
bankruptcy proceeding by or against a Party under the United States Bankruptcy Code, the other Party shall be entitled to complete access to any such intellectual property licensed to it hereunder, and all embodiments of such intellectual property,
but only as necessary for the purposes of exploitation of the licenses granted to the non-affected party under this Agreement and subject to payment of the applicable fees (if any) set forth in this Agreement through the effective date of any
termination hereunder. 

  
 -29- 

 (c) Either Party has the right, upon sixty (60) days prior written notice to the other
Party, to terminate this Agreement, including all licenses hereunder, if such other Party is in breach of its material obligations hereunder and has not cured such breach within sixty (60) days after receipt of written notice requesting cure of
the breach. Notwithstanding the foregoing, if the Party alleged to be in breach disputes such any allegation of material breach in writing within the applicable sixty (60) day period, the affected Party shall not have the right to terminate
this Agreement unless and until it is finally determined by arbitration conducted in accordance with Section 24 below that such material breach was committed by such Party, and such Party fails to cure such material breach within
sixty (60) days after such determination. 
 (d) CONEKSIS has the right, upon sixty (60) days prior written notice to CONKWEST, to
terminate this Agreement for any reason or no reason, including any or all Licenses granted by CONKWEST hereunder. 
 (e) CONKWEST shall
have the right to terminate this Agreement upon notice to CONEKSIS in the event that CONEKSIS, or any of its sublicensees, or any Third Party assigned or designated by CONEKSIS, or any of its sublicensees, takes any action, directly or indirectly,
or knowingly provides financial or other assistance, including legal or technical advice, directly or indirectly, to any Third Party to challenge to the validity, enforceability, scope, inventorship or ownership of any of the CONKWEST Patents or any
patent rights included within the FCCC Rights in any court or tribunal or before the United States Patent and Trademark Office or any patent office in a jurisdiction outside of the United States, or in any arbitration proceeding, including in
connection with an opposition proceeding or re-examination, and within thirty (30) days after written notice thereof by CONKWEST, CONEKSIS does not withdraw or cause to be withdrawn such action; provided, however, that CONKWEST shall not have
such right to terminate this Agreement if such action is taken with respect to a CONKWEST Patent that has been asserted against CONEKSIS, or any of its sublicensees, in a legal, court, administrative or other governmental proceeding. 

(f) In the event of termination of this Agreement by CONKWEST under subsections (c) or (e) above or by CONEKSIS under subsection
(d) above, the Licenses granted hereunder shall terminate, CONEKSIS will destroy the Biological Material and the CONKWEST Cell 

  
 -30- 

 
Lines and destroy all CONKWEST Confidential Information provided by CONKWEST to CONEKSIS hereunder within thirty (30) days following termination under such subsection, and CONEKSIS
specifically agrees to make no further use of the CONKWEST Existing Rights or the CONEKSIS Modifications for any purpose. For the avoidance of doubt, in the event of any such termination, the licenses and rights granted by CONEKSIS to CONKWEST
hereunder shall survive. 
 12. Assignment; Successors. This Agreement including the rights and privileges granted hereunder may not be assigned by
either Party without the prior written consent of the other Party; provided, however, that either Party may, without the other Party’s consent, assign this Agreement and its rights and obligations hereunder (a) to an Affiliate or
(b) in connection with the transfer or sale of all or substantially all of its business or assets, or in the event of its merger, consolidation, change in control or other similar transaction. This Agreement is binding upon and will inure to
the benefit of the Parties and their respective successors and permitted assigns. 
 13. Notice Address. Any payment, notice or other communication
pursuant hereto shall be sufficiently made or given if sent to the other Party by certified or registered mail postage prepaid, facsimile, or sent by nationally-recognized overnight courier addressed to it at its address below or at such other
address as a Party may later designate by written change of address notice given to the other Party in accordance with this Section 13. Any such notice shall be deemed to have been given: (a) when delivered if sent by facsimile on a
business day (or if delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) business day following
the date of mailing, if sent by mail. 
 If to CONKWEST: 

CONKWEST Incorporated 
 2533 South Coast Highway 101 

Suite 210 
 Cardiff-By-The-Sea, CA 92007-2133 

Attention: Barry J. Simon, M.D., 
 President & CEO

 Telephone: (858) 633-0300 
 Facsimile:
(858) 380-1999 
 E-mail: bsimon@conkwest.com 

  
 -31- 

 With copies to: 

Pietragallo Gordon Alfano Bosick & Raspanti, LLP 
 38th
Floor, One Oxford Centre 
 Pittsburgh, PA 15219 
 Attention:
Alicia M. Passerin, Ph.D, Esq. 
 Telephone: (412) 263-4369

Facsimile: (412) 261-0915 
 E-mail: AMP@Pietragallo.com 

If to CONEKSIS: 
 Conkesis, Inc. 

2533 South Coast Highway 101 
 Suite 210 

Cardiff-By-The-Sea, CA 92007-2133 
 Attention: Chief Executive
Officer 
 Telephone: (858) 633-0300 
 Facsimile:
(858) 380-1999 
 Email:
                                         

14. Headings. All headings are for convenience only and shall not affect the meaning of any provision hereof. 

15. Force majeure. If a Party (the “Non-Performing Party”) is unable to carry out any of its obligations under this Agreement due to
Force Majeure, this Agreement shall remain in effect but the Non-Performing Party’s relevant obligations under this Agreement and the corresponding obligations of the other Party (the “Innocent Party”) under this Agreement,
shall be suspended for a period equal to the circumstance of Force Majeure, provided that: 
 (a) the suspension of performance is of no
greater scope than is required by the Force Majeure; 
 (b) the Non-Performing Party gives the Innocent Party written notice describing the
circumstance of Force Majeure as soon as reasonably practical, including the nature of the occurrence; 

  
 -32- 

 (c) the Non-Performing Party uses all reasonable efforts to remedy its inability to perform and
to mitigate the effects of the circumstance of Force Majeure; and 
 (d) as soon as practicable after the event which constitutes Force
Majeure the Parties discuss how best to continue their operations as far as possible in accordance with this Agreement. 
 16. Entire Agreement. This
Agreement, together with any Appendices attached hereto and specifically referenced herein, contains the entire understanding of the Parties with respect to the subject matter herein and supersedes all previous agreements and undertakings with
respect thereto. 
 17. Miscellaneous: This Agreement may be amended only by a writing signed by the authorized representative of each of the
Parties. 
 18. Survival: The expiration or termination of this Agreement for any reason shall not release either Party from any liability that, at
the time of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expiration or termination, nor will any termination of this Agreement preclude either Party from pursuing all rights
and remedies it may have under this Agreement, or at law or in equity, with respect to any breach of this Agreement. In addition, the following provisions of the Agreement shall survive expiry or any termination of the Agreement: Sections 1, 2(b),
3, 5(g), 9, 10,11, 13, 14, this Section 18, 19, 20, 21, and 24 and all definitions relating to the foregoing. 
 19. Governing Law: This
Agreement shall be construed in accordance with the laws of the State of Delaware, and the patent laws of the United States, without regard or reference to any of its rules or provisions governing conflict of laws. 

20. Severance of Terms: If the whole or any part of this Agreement is or becomes or is declared illegal, invalid or unenforceable in any jurisdiction
for any reason (including both by reason of the provisions of any legislation and also by reason of any decision of any court or competent authority which either has jurisdiction over this Agreement or has jurisdiction over any of the Parties): 

(a) in the case of the illegality, invalidity or unenforceability of the whole of this Agreement it shall terminate in relation to the
jurisdiction in question; or 

  
 -33- 

 (b) in the case of the illegality, invalidity or unenforceability of part of this Agreement that
part shall be severed from this Agreement in the jurisdiction in question and that illegality, invalidity or unenforceability shall not in any way whatsoever prejudice or affect the remaining parts of this Agreement which shall continue in full
force and effect unless the absence of the invalidated, illegal or unenforceable provisions(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their reasonable good faith efforts to replace the
invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. 

21. Waiver. The waiver by a Party of any right hereunder, or of any failure of the other Party to perform, or of any breach or violation of any
provision hereof by the other Party shall not operate or be construed a waiver of any other right hereunder or of any other subsequent failure, breach or violation of such other Party hereof whether of a similar nature or otherwise. 

22. Export. It is understood that the Biological Material and Know-How provided or made available by CONKWEST under this Agreement may be subject to
applicable laws and regulations controlling the export and import of technical data, biological materials, laboratory prototypes, and other information or materials that may require a license from the applicable agency of the United States
Government or foreign government, and CONEKSIS will comply with all such laws and regulations in the performance of this Agreement. CONKWEST neither represents that a license will not be required nor does CONKWEST represent that if a license is
required, it will be issued. 
 23. Counterparts; Telefacsimile, Electronic Execution. This Agreement may be executed in any number of counterparts
(facsimile and electronic transmission included), and by each of the Parties on separate counterparts, each of which, when so executed, shall be deemed an original, but all of which shall constitute but one and the same instrument. After facsimile
or electronic transmission, the Parties agree to execute and exchange documents with original signatures. 

  
 -34- 

 24. Dispute Resolution. 

(a) The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to
this Agreement or the performance or breach thereof. If the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not an “Excluded Claim” shall be finally resolved by binding
arbitration in accordance with the Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association (“AAA”), and judgment on the arbitration award may be entered in any
court having jurisdiction thereof. 
 (b) The arbitration shall be conducted by a panel of three persons experienced in the pharmaceutical
business: within thirty (30) days after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within thirty (30) days of their appointment.
If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the AAA. The place of arbitration shall be San Diego, California, and all proceedings and communications
shall be in English. 
 (c) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered
or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party
pending the arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages. Each Party shall bear its own costs and expenses and attorneys’ fees and
an equal share of the arbitrators’ fees and any administrative fees of arbitration. 
 (d) Except to the extent necessary to confirm an
award or as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties; provided that either Party may make such disclosures as are
permitted for Confidential Information of the other Party under Section 10 above. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would
be barred by the applicable Delaware statute of limitations. 

  
 -35- 

 (e) The Parties agree that, in the event of a good faith dispute over the nature or quality of
performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. The Parties further agree that any payments made pursuant to this Agreement
pending resolution of the dispute shall be refunded if an arbitrator or court determines that such payments are not due. 
 (f) As used in
this Section, the term “Excluded Claim” means a dispute, controversy or claim that concerns (a) the validity or infringement of a patent, trademark or copyright; or (b) any antitrust, anti-monopoly or competition law or
regulation, whether or not statutory; or (c) the misappropriation of any trade secret or breach of confidentiality obligation under this Agreement. 

SIGNATURE PAGE FOLLOWS 

  
 -36- 

 SIGNATURE PAGE TO NON-EXCLUSIVE LICENSE AGREEMENT 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives. 

 

									
	CONKWEST INCORPORATED:				CONEKSIS, INC.
					
	By:		 /s/ Barry J. Simon
				By:		 /s/ Barry J. Simon

	Name:		Barry J. Simon, M.D.				Name:		Barry J. Simon, M.D.
	Title:		President and COO				Title:		President and CEO
	Date:		June 9, 2015				Date:		June 9, 2015

  
 -37- 

 SCHEDULE A 

[***] 

  
 -1- 

 APPENDIX B 

CONKWEST KNOW-HOW 

[***] 

  
 -1- 

 SCHEDULE C 

CONKWEST MARKS 
 [***]

  
 -2- 

 SCHEDULE D – FCCC Patents and Patent Applications 

[***] 

  
 -3-EX-10.9

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Exhibit 10.9 
 JOINT
DEVELOPMENT AND LICENSE AGREEMENT 
 This Joint Development and License Agreement (this “Agreement”) is
made and entered into as of the 18th day of December, 2014 (the “Effective Date”), by and between CONKWEST INCORPORATED, a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210,
Cardiff-By-The-Sea, CA 92007-2133 (“CONKWEST”), and SORRENTO THERAPEUTICS, INC., a Delaware corporation with offices at 6042 Cornerstone Ct. W., San Diego, Ca 92121 (“SRNE”). CONKWEST and SRNE are sometimes
referred to herein individually as a “Party” and together as the “Parties.” 
 Recitals 

WHEREAS, CONKWEST is an innovative life sciences company that owns all rights, title, and interest in and to certain CONKWEST
Existing Rights, including, but not limited to, the CONKWEST Cell Line, CONKWEST Master Cell Bank, and CONKWEST Working Cell Bank, and has the right to grant licenses thereto; and 

WHEREAS, CONKWEST has commercialized and is continuing to commercialize the CONKWEST Cell Line and variants thereof for use in
a variety of diagnostic and therapeutic applications, including for use in the treatment of cancers and infections; and 

WHEREAS, SRNE owns all rights, title, and interest in and to certain SRNE Existing Rights, including but not limited to
certain proprietary tissue targeting moiety (“TTM”) including but not limited to chimeric antigen receptors and their corresponding genetic sequences (the “SRNE TTM(s)”); 

WHEREAS, CONKWEST and SRNE desire to exclusively collaborate in a Program (defined below) of any and all Projects, each
Project intended to facilitate the joint development of certain TTM modified proprietary effector cell lines, including the CONKWEST Cell Line, CONKWEST Master Cell Bank, CONKWEST Working Cell Bank, NK cell lines, and/or T cell lines (collectively,
the “Effector Cell Line(s)”), including any and all TTM-modified Effector Cell Lines and Effector Cell Line derivatives (the “Joint Cell Line(s)”) for therapeutic applications (the “Joint Product(s)”); and 

WHEREAS, concurrently with the execution of this Agreement, CONKWEST and SRNE are entering into a Subscription and Investment
Agreement, in the form attached hereto as Exhibit A (the “Investment Agreement”), and a Registration Rights Agreement, in the form attached hereto as Exhibit B (the “Registration Rights Agreement”). NOW, THEREFORE, in
consideration of the foregoing and the mutual covenants contained in this Agreement, the Parties, intending to be legally bound, agree as follows: 

ARTICLE 1 

DEFINITIONS 
  

			
	 1.1
		 “BLA” means the Biological License Application (together with any other required registrations, notifications or forms) for any Joint Product (and/or
pre-market approval to make and sell commercially any Joint Product) filed with the FDA.

  

			
	 1.2
		 “CAR(s)” means a chimeric antigen receptor consisting of a monoclonal antibody or a functional part thereof, a transmembrane domain, and one or more
signaling domains capable of activating Effector Cell Line that confers a cell or tissue specificity onto the Effector Cell Line.

		
	 1.3
		 “Clinical Trials” means clinical studies conducted in humans anywhere in the world in accordance with GCPS.

		
	 1.4
		 “Confidential Information” has the meaning set forth in the Mutual Confidentiality Agreement.

		
	 1.5
		 “CONKWEST Cell Line” means [***].

		
	 1.6
		 “CONKWEST Confidential Information” means all Confidential Information that is owned or Rightfully Used by CONKWEST.

		
	 1.7
		 “CONKWEST Existing Rights” means CONKWEST Rights existing as of the Effective Date.

		
	 1.8
		 “CONKWEST Intellectual Property Rights” means all CONKWEST Know-How, CONKWEST Patents, and all other Intellectual Property Rights pertaining to the
CONKWEST Cell Line that are owned or Rightfully Used by CONKWEST but which are not Joint Product Rights (including, for clarity, any Developed Intellectual Property Rights that CONKWEST identifies, discovers, invents, acquires, and/or develops after
the Effective Date but which are not Joint Product Rights).

		
	 1.9
		 “CONKWEST Know-How” means all Know-How pertaining to the CONKWEST Cell Line that is owned or Rightfully Used by CONKWEST but which is not a Joint
Product Right (including, for clarity, any Developed Know-How that CONKWEST identifies, discovers, invents, acquires, and/or develops after the Effective Date but which is not a Joint Product Right). CONKWEST Know-How does not include CONKWEST
Patents.

		
	 1.10
		 “CONKWEST Master Cell Bank” means the GMP-certified CONKWEST Cell Line. CONKWEST Master Cell Bank does not include any modifications, derivations, or
improvements to the CONKWEST Cell Line.

		
	 1.11
		 “CONKWEST Patents” means the Patents pertaining to the CONKWEST Cell Line that are listed on Schedule 2 hereto, which may be updated from time to
time, and any Developed Patents (including patent applications) filed by or on behalf of CONKWEST which are not Joint Product Rights.

		
	 1.12
		 “CONKWEST Rights” means CONKWEST Cell Line, CONKWEST Intellectual Property Rights, CONKWEST Master Cell Bank, and CONKWEST Working Cell
Bank.

		
	 1.13
		 “CONKWEST Working Cell Bank” means the GLP and cGMP unmodified CONKWEST Cell Line. CONKWEST Working Cell Bank does not include any modifications,
derivations, or improvements to the CONKWEST Cell Line.

  
 2 

			
	 1.14
		 “Copyrights” means all copyrights and other works of authorship, and all rights, title and interests in and to all copyrights, works of authorship,
copyright registrations and applications for copyright registration, certificates of copyright and copyrighted interests, and all other rights of any kind or nature therein, arising under any law anywhere in the world.

		
	 1.15
		 “Costs” shall have the meaning specified in Section 2.4(c) hereto.

		
	 1.16
		 “Developed Intellectual Property Rights” means all Developed Know-How, Developed Patents, all other Intellectual Property Rights identified,
discovered, invented, acquired, and/or developed after the Effective Date by SRNE and/or CONKWEST (separately or jointly, as well as including any subcontractors and/or agents thereof) in the course of and specifically related to at least one
Project in the Program, including those using or based upon the Intellectual Property Rights of the other Party.

		
	 1.17
		 “Developed Know-How” means all Know-How that is identified, discovered, invented, acquired and/or developed after the Effective Date by SRNE and/or
CONKWEST (separately or jointly, as well as including any subcontractors and/or agents thereof) in the course of and specifically related to at least one Project in the Program, including those using or based upon the Intellectual Property Rights of
the other Party. Developed Know-How does not include Developed Patents. Notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that Developed Know-How specifically excludes: (i) any Know-How constituting
SRNE Existing Rights, and (ii) any Know-How constituting CONKWEST Existing Rights.

		
	 1.18
		 “Developed Patents” means all Patents filed by or on behalf of either Party that claim subject matter identified, discovered, invented, acquired
and/or developed after the Effective Date by SRNE and/or CONKWEST (separately or jointly, as well as including any subcontractors and/or agents thereof) in the course of and specifically related to at least one Project in the Program, including
those using or based upon the Intellectual Property Rights of the other Party. Notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that Developed Patents specifically exclude: (i) any Patents
constituting SRNE Existing Rights, and (ii) any Patents constituting CONKWEST Existing Rights.

		
	 1.19
		 “Effective Date” means the date stated in the opening paragraph of this Agreement.

		
	 1.20
		 “Effector Cell Line(s)” has the meaning specified in the preamble of this Agreement.

		
	 1.21
		 “Excluded CARs” means the following CARs: [***].

		
	 1.22
		 “Excluded Products” means any products that include an Excluded CAR and/or any product used for or in connection with any of the following:
[***]

		
	 1.23
		 “FDA” means the United States Food and Drug Administration or any successor agency having the administrative authority to regulate the approval for
marketing of new human pharmaceutical and biological products in the United States, and any equivalent authority in any jurisdictions outside of the United States.

  
 3 

					
	 1.24
		 “Feasibility Work” means any preliminary work required in order for the Steering Committee to select
which, if any, Joint Cell Line(s) and/or Joint Product(s) shall be pursued as part of the Program, where such preliminary work may include selection of the CAR(s), creation of the Joint Cell Line(s), and/or generation of in vitro data relating to
such Joint Cell Line(s).

		
	 1.25
		 “Final Report” has the meaning specified in Section 5.2 of this Agreement.

		
	 1.26
		 “GCPS” means the then-current Good Clinical Practice Standards, as defined in the
U.S. regulations, 21 CFR, and as further elaborated by the FDA in applicable guidance documents, together with equivalent regulations and requirements in jurisdictions outside of the United States.

		
	 1.27
		 “GLP” means the then-current Good Laboratory Practices, as defined in the U.S. regulations, 21 CFR
§ 58, and as further elaborated by the FDA in applicable guidance documents, together with equivalent regulations and requirements in jurisdictions outside of the United States.

		
	 1.28
		 “GMP” means the then-current Good Manufacturing Practices, as defined in the U.S. regulations, 21
CFR §§ 210 and 211, and as further elaborated by the FDA in applicable guidance documents, together with equivalent regulations and requirements in jurisdictions outside of the United States.

		
	 1.29
		 “Government Authority” means any supranational, national, regional, state or local government, court,
governmental agency, authority, board, bureau, instrumentality or regulatory body.

		
	 1.30
		 “Gross Revenue” means gross receipts actually received by or on behalf of a Party from sales of all
[***].

		
	 1.31
		 “Infringement Action” has the meaning specified in Section 6.3(b) of this Agreement.

		
	 1.32
		 “Insolvency Event” means with respect to any Party, the occurrence of any one of the following
events:

			
			 (a)
		 a court of competent jurisdiction shall have entered a decree or order for relief in respect of the Party in an involuntary proceeding under any applicable
United States bankruptcy, insolvency, reorganization or other similar law now or hereafter in effect, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or other similar official) of the Party or of all or any
substantial part of its property, or ordering the winding up or liquidation of its affairs, and such decree or order shall remain unstayed and in effect for a period of sixty (60) consecutive days; or

			
			 (b)
		 the Party shall have commenced a voluntary proceeding under any applicable United States bankruptcy, insolvency, reorganization or other similar law now or
hereafter in effect, or shall have consented to the entry of an order for relief in an involuntary case under any such law, or shall have consented to the appointment

  
 4 

					
					 of or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator (or other similar official) of the Party or of all or any
substantial part of its property, or shall have made an assignment for the benefit of creditors; or

			
			 (c)
		 the Party shall have failed generally to pay its debts as they become due or shall have taken any corporate action in furtherance of any of the matters referred
to in clause (b) above.

		
	 1.33
		 “Intellectual Property Rights” means, collectively, Patents, Know-How, Copyrights, moral rights, and
all other like technology and related intellectual property rights anywhere in the world.

		
	 1.34
		 “Joint Cell Line(s)” has the meaning specified in the preamble of this Agreement.

		
	 1.35
		 “Joint IND” means the Investigational New Drug Application (IND) for a Joint Cell Line and/or a
Joint Product.

		
	 1.36
		 “Joint Master Cell Bank(s)” means the GMP-certified Joint Cell Line(s).

		
	 1.37
		 “Joint Patents” has the meaning set forth in Section 6.2(d) of this Agreement.

		
	 1.38
		 “Joint Product(s)” has the meaning set forth in the preamble of this Agreement.

		
	 1.39
		 “Joint Product Rights” means the Joint IND associated with a Joint Cell Line or Joint Product, and the
Developed Intellectual Property Rights in the Joint Cell Line(s), Joint Master Cell Bank, Joint Working Cell Bank, and Joint Products.

		
	 1.40
		 “Joint Working Cell Bank” means the GLP-certified Joint Cell Line(s).

		
	 1.41
		 “Know-How” means all technical and other information, data, methods, inventions (whether patentable or not and whether or not reduced to
practice), trade secrets, and similar proprietary rights and other know-how and trade secret rights arising under any law anywhere in the world.

		
	 1.42
		 “Mutual Confidentiality Agreement” means the Mutual Confidentiality Agreement between CONKWEST and SRNE
entered into on November 1, 2014.

		
	 1.43
		 “Party” and “Parties” have the meanings stated in the opening paragraph of this
Agreement.

		
	 1.44
		 “Patents” means all patents, patent applications, utility models, including any extension,
registration, confirmation, continuation-in-part, reissue, re-examination, supplementary protection certificate or renewals thereof including, without limitation any foreign equivalents thereof, and all rights of any kind or nature therein arising
under any law anywhere in the world.

  
 5 

			
	 1.45
		 “Person” means an individual, partnership, firm, corporation, limited liability company, joint venture, association, trust or other entity or any
government agency or political subdivision thereof.

		
	 1.46
		 “Phase I Clinical Trial” means a phase I or a phase I/II Clinical Trial in any country that is intended to initially evaluate the safety and/or
therapeutic or antigenic effect of a Joint Cell Line in human subjects that would satisfy the requirements of 21 C.F.R. § 312.21(a), as amended, if such Clinical Trial was conducted in the U.S.

		
	 1.47
		 “Phase II Clinical Trial” means a phase II, phase IIb or a phase II/III Clinical Trial in any country that is intended to initially evaluate the
effectiveness of a Joint Cell Line for a particular indication under study that would satisfy the requirements of 21 C.F.R. § 312.21(b), as amended, if such Clinical Trial was conducted in the U.S. For clarity, a Phase II Clinical Trial shall
not include a phase I/II Clinical Trial.

		
	 1.48
		 “Phase III Clinical Trial” means all tests and studies in patients (other than Phase I and Phase II Clinical Trials) that are intended to provide
substantial evidence of efficacy and safety in support of a BLA for a Joint Cell Line, including pivotal trials and all tests and studies that are required by the applicable Regulatory Agency from time to time, pursuant to regulations, guidelines or
otherwise, as Phase III Clinical Trials tests and studies for the Joint Cell Line, including the trials referred to in 21 C.F.R. § 312.21(c), as amended, in the case of such Clinical Trials in the U.S.

		
	 1.49
		 “Pre-Approved” means approved by the Steering Committee as set forth in Section 2.1 prior to any development, testing, Regulatory Approval, or
commercialization.

		
	 1.50
		 “Primary Party” has the meaning specified in Section 2.4 of this Agreement.

		
	 1.51
		 “Principal Investigator” has the meaning specified in Section 2.4(a)(iii) of this Agreement.

		
	 1.52
		 “Progress Reports” has the meaning specified in Section 5.1 of this Agreement.

		
	 1.53
		 “Program” means a series of Projects.

		
	 1.54
		 “Project” means collaborative research and development by the Parties relating to the use of CONKWEST’s Existing Rights and SRNE’s Existing
Rights, the details of which are set forth in Article 2 hereto and in Statements of Work which may be agreed upon by the Parties and which will become part of this Agreement. For purposes of clarity, (i) the Project(s) expressly exclude the
Excluded CARs; (ii) the inclusion of any of CONKWEST’s Existing Right(s) and/or SRNE’s Existing Right(s) in a first Project does not preclude the inclusion of such Existing Rights in a subsequent Project that is governed by separate
Statement(s) of Work and may be driven by a different Primary Party from the first Project, and (iii) the inclusion of Jointly Developed Products in a subsequent Project that is governed by separate Statement(s) of Work and may be driven by a
different Primary Party from the first Project.

  
 6 

			
	 1.55
		 “Regulatory Approval” means, with respect to a state, nation or multinational jurisdiction, (i) any approvals, licenses, registrations or
authorizations necessary for the manufacture (where relevant), marketing and sale of a Joint Cell Line or Joint Product in such state, nation or jurisdiction, and (ii) where relevant, pricing approvals necessary to obtain reimbursement from a
Government Authority.

		
	 1.56
		 “Research Credit Payment” means the research credit payment by SRNE to CONKWEST for funding the development of any Joint Product(s) to be determined
by CONKWEST in the amount of $[***].

		
	 1.57
		 “Revenue” means the sum total of Gross Revenue and Sublicensing Revenue, provided that, for clarity all equity investments and similar consideration
received by a Party in connection with a Strategic Transaction shall not and shall not be deemed to be Revenue hereunder.

		
	 1.58
		 “Rightfully Use” means, with respect to any Intellectual Property Rights owned by a Third Party, that a Party has an interest therein sufficient to
enable it to (a) use such Intellectual Property Rights and (b) grant to the other Party a license or sublicense to use such Intellectual Property Rights, in either case without violating the terms of any agreement or other arrangement with
or Intellectual Property Rights of any Third Party.

		
	 1.59
		 “Secondary Party” has the meaning specified in Section 2.4 of this Agreement.

		
	 1.60
		 “SRNE TTMs” has the meaning set forth in the preamble to this Agreement and includes, but is not limited to, the following initial TTMs:
[***].

		
	 1.61
		 “SRNE Confidential Information” means all Confidential Information that is owned or Rightfully Used by SRNE.

		
	 1.62
		 “SRNE Existing Rights” means SRNE Rights existing as of the Effective Date.

		
	 1.63
		 “SRNE Intellectual Property Rights” means all SRNE Know-How, SRNE Patents, and all other Intellectual Property Rights that are owned or Rightfully
Used by SRNE but which are not Joint Product Rights (including, for clarity, any Developed Intellectual Property Rights that SRNE identifies, discovers, invents, acquires, and/or develops after the Effective Date but which are not Joint Product
Rights).

		
	 1.64
		 “Sorrento Introduced Investor/s” means one or more Third Party investors introduced to Conkwest by an officer or director of SRNE.

		
	 1.65
		 “SRNE Know-How” means all Know-How that is owned or Rightfully Used by SRNE but which is not a Joint Product Right (including, for clarity, any
Developed Know-How that SRNE identifies, discovers, invents, acquires, and/or develops after the Effective Date but which is not a Joint Product Right). SRNE Know-How does not include SRNE Patents.

  
 7 

			
	 1.66
		 “SRNE Patents” means the Patents that are listed on Schedule 3 hereto, which may be updated from time to time, and any Developed Patents
(including patent applications) filed by or on behalf of SRNE which are not Joint Product Rights.

		
	 1.67
		 “SRNE Rights” means the SRNE TTMs and SRNE Intellectual Property Rights.

		
	 1.68
		 “Statement of Work” means the written description(s) of the research and development activities for accomplishing a Project, a template of which is
provided in Schedule 1 of this Agreement.

		
	 1.69
		 “Steering Committee” means a committee made up of representatives from each Party and which is tasked with managing the relationship between the
Parties with respect to the Program and overseeing the particular Projects making up the Program.

		
	 1.70
		 “Strategic Transaction” means a financing event, joint venture, merger, acquisition, change in control, equity investment, or initial public offering
involving a Party, or a sale of all or substantially all of a Party’s business or assets relating to this Agreement.

		
	 1.71
		 “Sublicensing Revenue” means all fees, consideration, and other amounts, including milestone payments and royalties, actually received by or on behalf
of a Party from the licensing or sublicensing of Joint Product Rights, provided that, for clarity, (i) amounts received by a Party in connection with performing sponsored research, (ii) clinical trial costs, (iii) FTE, and (iv) equity investments
and similar consideration received by a Party in connection with a Strategic Transaction shall not and shall not be deemed to be Sublicensing Revenue hereunder.

		
	 1.72
		 “Term” has the meaning specified in Section 12.1 of this Agreement.

		
	 1.73
		 “Termination Date” means the effective date of any Termination Notice.

		
	 1.74
		 “Termination Notice” means a written notice delivered by one Party to the other Party of its election to terminate this Agreement pursuant to
Article 12 of this Agreement.

		
	 1.75
		 “Third Party” means any Person other than CONKWEST or SRNE.

		
	 1.76
		 “Third Party Rights” has the meaning specified in Section 3.4 of this Agreement.

		
	 1.77
		 “Tissue Targeting Moiety” and/or “TTM” means a molecular moiety and expressed or presented on the surface of a cell that enables the
targeting of the cell to specific cells or tissue. The molecular moiety includes but is not limited to a CAR.

		
	 1.78
		 “United States” means the United States of America, including the District of Columbia and the Commonwealth of Puerto Rico.

		
	 1.79
		 “Wind Down Procedures” means diligent efforts by each of the Parties to wind down and terminate a Project or the Program as quickly as possible and in
a commercially reasonable manner. As a part of the Wind Down Procedures, each Party shall use its best efforts to minimize any further costs and expenses associated with a Project or the Program, as the case may be.

  
 8 

 ARTICLE 2 

PROJECTS COMPRISING THE PROGRAM BETWEEN THE PARTIES 
  

					
	 2.1
	 	 Steering Committee. The Steering Committee shall be made up of three (3) members from each Party,
with each member having one vote. The Steering Committee shall be tasked with general oversight of the Program and with specific management of each Project making up the Program as set forth in this Section 2.1.

			
		 	 (a)
	 	 Meetings. The Steering Committee shall meet (i) quarterly during the Term, (ii) at any other intervals as may be mutually agreed, and (iii) otherwise at
the request of either Party upon the provision of at least five (5) days prior written notice to the other Party. Meetings may be held in person, by telephone, or by video conference call, and the location of each meeting shall alternate between the
offices of the Parties (or any other venue as may be agreed between the Parties in writing).

			
		 	 (b)
	 	 Quorum. Meetings of the Steering Committee shall require a quorum consisting of at least two (2) members of each Party; provided, however, that a quorum
shall only be reached upon full attendance of all Steering Committee members to address any items that would affect the scope or terms or conditions of this Agreement (including any decisions pertaining to the Projects or the Program, or financial
terms and conditions). If such quorum is not present within one hour from the time appointed for the meeting, those members who did attend shall jointly issue a notice to re-convene the meeting at the same place and time at least seven (7) days
later. If the Steering Committee fails to convene for three consecutive times upon the notice of a meeting, the issues to be discussed and decided by the Steering Committee as provided in the meeting notice shall be finally determined by those
members of the Steering Committee in attendance at the next scheduled Steering Committee meeting, regardless of whether the required quorum is met.

			
		 	 (c)
	 	 Votes; Binding Effect. Any determination of the Steering Committee shall be made by a majority vote of all Steering Committee members in which the quorum
requirement set forth in Section 2.1(b) is met and shall be binding upon the Parties. If there is a deadlock in any matter to be decided by the Steering Committee, then the CEOs of each Party shall, if requested by either Party, meet and confer and
attempt to resolve such deadlock.

			
		 	 (d)
	 	 Minutes. The Steering Committee shall keep full and complete minutes of the Steering Committee meetings and each Party shall retain a copy of such
minutes for their record. SRNE shall be responsible for preparing and distributing the minutes of the first Steering Committee meeting. Thereafter, minutes shall be prepared by each respective party on an alternating basis. The Party
responsible

  
 9 

									
					 for preparing the minutes shall provide a copy of such minutes to the other Party and such other Party shall be
given the opportunity to review and comment thereon. The minutes shall be filed by Steering Committee and the Parties in accordance with this provision upon the reasonable approval of the Party that did not prepare the minutes.

			
			 (e)
		 Responsibilities of the Steering Committee. For each potential Project or Project, as the case may be, the
Steering Committee shall be tasked with at least the following action items:

					
							 (i)
		 Selecting which potential Projects will be advanced to the stage of performing Feasibility Work;

					
							 (ii)
		 For any potential Project, drafting and agreeing upon an initial Statement of Work for carrying out the Feasibility Work for such potential Project, such
Statement of Work to include, among other things, the scope of the Feasibility Work, which Party is to carry out the Feasibility Work (assuming a Primary Party has not been identified yet), where the Feasibility Work is to be performed, and
allocation of costs between the Parties

					
							 (iii)
		 identifying which Party shall be the Primary Party and which Party shall be the Secondary Party, provided that if a potential Project is initiated by a Party in
response to actual or potential collaboration with a Third Party, then such Party shall be the Primary Party with respect to such Project;

					
							 (iv)
		 drafting and agreeing upon the various Statement(s) of Work for carrying out the Project,

					
							 (v)
		 allocating the financial responsibility(ies) for performing such Project among the Primary and Secondary Parties, and

					
							 (vi)
		 selecting which, if any, Joint Cell Lines and/or Joint Products shall be pursued as part of such Project.

			
					 Each Project shall continue unless and until terminated by the Primary Party, provided that the Secondary Party
shall have the right to exercise its option, as set forth in Article 4, for any Project which the Primary Party elects to discontinue.

			
					 The Program shall continue for the later of three (3) years or until the last to expire Project.

		
	 2.2
		 Projects; Exclusivity. The Parties hereby agree to exclusively collaborate in the Program for the purpose
of jointly developing any and all TTM-modified Effector Cell Lines. The Parties agree that such exclusivity extends to any SRNE Rights or any CONKWEST Rights included in a Project. By way of non-limiting example, SRNE agrees that any monoclonal
antibody used to develop a Project CAR shall be used exclusively for that

  
 10 

									
		 	 Project and shall not be the subject of any relationship with a Third Party in any TTM-modified Effector Cell
Line-based therapy, excluding the purified recombinant antibody or antibody drug conjugates (ADC) format of the monoclonal antibody. Again by way of non-limiting example, CONKWEST agrees that it shall not work with any Third Party on any
TTM-modified Effector Cell Line-based therapy. Further, CONKWEST acknowledges and agrees that CD16 expressing NK-92 cell lines may not be used by Conkwest in connection with TTM without SRNE’s express prior written consent, and CONKWEST will
not license nor permit or assist any Third Party use TTM in connection with any CD16 expressing NK-92 cell lines. If CONKWEST desires to use CD16 expressing NK-92 cell lines as an Effector Cell Line or otherwise in connection with TTM, then CONKWEST
must do so under the terms and conditions of this Agreement and the CD16 expressing NK-92 cell lines shall be and be deemed to be included within the definition “Effector Cell Line” and subject to the exclusive rights of SRNE hereunder.
For each Project making up the Program, each Party shall work and collaborate exclusively with the other Party with respect to the subject matter of such Project and shall conduct the Project in accordance with the terms of this Agreement and as set
forth in the various Statements of Work as they may be agreed to by the Parties in writing from time to time. During the Term, the Parties agree to work and collaborate exclusively with the other Party with respect to any and all Joint Cell Lines
and Joint Products.

		
	 2.3
	 	 Initial Responsibilities of Each Party. At points in time and in accordance with terms set forth in this
Agreement and/or a Statement of Work, as applicable:

			
		 	 (a)
	 	 CONKWEST shall:

					
		 		 		 	 (i)
	 	 within five (5) business days of the Effective Date of this Agreement, notify SRNE of the names of and contact information for three
(3) representatives to serve on the Steering Committee;

					
		 		 		 	 (ii)
	 	 provide to SRNE the CONKWEST Know-How and other information related to the CONKWEST Cell Line, solely to the extent set forth and specified in the applicable
Statement of Work;

					
		 		 		 	 (iii)
	 	 supply to SRNE [***] vials of cells from the CONKWEST Working Cell Bank, solely to the extent set forth and specified in the applicable Statement of
Work;

					
		 		 		 	 (iv)
	 	 supply to SRNE [***] vials of cells from the CONKWEST Master Cell Bank, solely to the extent set forth and specified in the applicable Statement of
Work;

			
		 		 	 provided, however, that SRNE’s use of all materials provided by CONKWEST pursuant to this Section 2.3(a)
shall be for the sole purpose of performing the Program in accordance with this Article 2 and subject to the license granted in Article 3 hereto; and

  
 11 

									
			 (b)
		 SRNE shall:

					
							 (i)
		 within five (5) business days of the Effective Date of this Agreement, notify CONKWEST of the names of and contact information for three
(3) representatives to serve on the Steering Committee;

					
							 (ii)
		 pay the Research Credit Payment to CONKWEST to fund development of Joint Cell Lines and Joint Products, of which [***];

					
							 (iii)
		 SRNE agrees to purchase shares of common stock of CONKWEST, and CONKWEST agrees to sell shares of its common stock SRNE, in each case pursuant to the terms of
the Investment Agreement and MOU. The shares of common stock of CONKWEST sold and issued to SRNE under the Investment Agreement shall have the registration rights set forth in the Registration Rights Agreement;

					
							 (iv)
		 permit CONKWEST, at CONKWEST’s sole cost, to locate a laboratory on the SRNE premises either using an offset to the Research Credit Payment or by charging
CONKWEST the fees as mutually agreed upon, provided that CONKWEST will remain solely liable for its activities and conduct in such laboratory, will comply with all laws, regulations, rules, and guidelines applicable to SRNE’s premises, will
obtain all necessary Government Approvals for such laboratory, and will fully indemnify, defend, and hold SRNE harmless from and against any and all claims, costs, liabilities, causes of action, and damages arising out of or associated with such
laboratory and CONKWEST’s conduct therein. If this Agreement is terminated or expires, SRNE shall provide CONKWEST period of one (1) year from the termination or expiration date in which to relocate such laboratory;

					
							 (v)
		 provide to CONKWEST the SRNE Know-How and other information related to the SRNE TTM(s), solely to the extent set forth and specified in the applicable Statement
of Work; and

					
							 (vi)
		 supply to CONKWEST, as soon as it may be available, but no later than three (3) months from the effective date of the Steering Committee approving a Project, an
initial supply of the SRNE TTM sequences selected for NK-92 modification in such Project, solely to the extent set forth and specified in the applicable Statement of Work;

			
					 provided, however, that CONKWEST’s use of such materials provided by SRNE shall be for the sole purpose of
performing the Program in accordance with this Article 2 and subject to the license granted in Article 3 hereto.

  
 12 

									
	 2.4
		 Joint Cell Line(s); Joint Product(s). As set forth in this Article 2 and in a Statement of Work(s) to
be agreed to by the Parties in accordance with Section 2.1 for each Joint Cell Line and/or Joint Product in a Project, the development, testing, Regulatory Approval, and/or commercialization of such Joint Cell Line and/or Joint Product shall be
driven by one Party (the “Primary Party”), with the other Party referred to as the “Secondary Party”. Unless indicated to the contrary in the applicable Statement of Work, the Primary Party for a given Project will have the right
and authority to initiate and control the development, testing, Regulatory Approval, or commercialization of the Joint Product or Joint Cell Line subject to such Project, including the right to make, have made, use, sell, have sold, import, and
otherwise commercialize such Joint Product or Joint Cell Line, and to license and sublicense all applicable Intellectual Property Rights (including Joint Product Rights) with respect thereto. Unless indicated to the contrary in a Statement of Work,
the rights and responsibilities of the Primary Party and the Secondary Party for each Joint Cell Line and/or Joint Product shall be as follows:

			
			 (a)
		 Rights and Responsibilities of the Primary Party. Unless otherwise agreed to in writing by both Parties
for a Project, the Primary Party shall have the following rights and responsibilities:

					
							 (i)
		 developing a Statement of Work(s) setting forth a plan for development and testing of any Joint Cell Line and/or Joint Product with milestones and timelines,
and presenting the Statement of Work to the Steering Committee for approval;

					
							 (ii)
		 creating a budget for implementation of the Statement of Work(s) and presenting the budget to the Steering Committee and CEOs of each Party for
approval;

					
							 (iii)
		 assigning an internal principal investigator for directing the implementation of the Project (the “Principal Investigator”); provided, however, that
if, for any reason, the Principal Investigator becomes unavailable, the Primary Party immediately shall provide the Secondary Party with written notification of the Principle Investigator’s unavailability and shall identify a successor, subject
to approval by the Secondary Party, which approval shall not be unreasonably delayed or denied;

					
							 (iv)
		 providing accurate and timely reports to the Steering Committee regarding progress toward milestones and use of funds;

					
							 (v)
		 carrying out the development, testing, Regulatory Approval, and/or commercialization of the applicable Joint Cell Line and/or Joint Product as set forth in the
Statement of Work;

					
							 (vi)
		 booking the sales as revenue for the specific Joint Cell Line and/or Joint Product as set forth in the Statement of Work;

  
 13 

									
							 (vii)
		 soliciting and executing out-licensing, discovery, development, marketing and/or distribution deals with a Third Party for the specific Joint Cell Line and/or
Joint Product as set forth in the Statement of Work, provided that the Secondary Party shall be provided with prior written notice of and right to comment on such deal, such comment to be given fair consideration by the Primary Party;
and

					
							 (viii)
		 if desired, forming a joint venture with a Third Party for the discovery, development and/or commercialization of the specific Joint Cell Line and/or Joint
Product as set forth in the Statement of Work, provided, however, that the Secondary Party shall be provided with prior written notice of and right to comment on such joint venture, such comment to be given fair consideration by the Primary
Party.

			
			 (b)
		 Rights and Responsibilities/Authority of the Secondary Party. Unless otherwise agreed to in writing by
both Parties, the Secondary Party shall have the following responsibilities and authority:

					
							 (i)
		 paying its pro rata share of all costs associated with the development, testing, Regulatory Approval, or commercialization of such Joint Cell Line and/or Joint
Product in accordance with Section 2.4(c) hereto;

					
							 (ii)
		 cooperating with the Primary Party and, upon request and at the Primary Party’s expense, providing reasonable assistance in connection with the
development, testing, Regulatory Approval and/or commercialization of the applicable Joint Cell Line and/or Joint Product;

					
							 (iii)
		 cooperating with the Primary Party and, upon request and at the Primary Party’s expense, providing reasonable assistance in connection with out-licensing,
discovery, development, or commercialization of the applicable Joint Cell Line and/or Joint Product with a Third Party that the Primary Party has a joint venture or licensing deal; and

					
							 (iv)
		 attending any meetings with regulatory agencies, including but not limited to the FDA, legal proceedings, or other meetings or proceedings that relate to Joint
Product Rights, or its own Intellectual Property or Cell Line(s), e.g., CONKWEST Intellectual Property or CONKWEST Cell Lines, or SRNE Intellectual Property or SRNE TTMs, , as the case may be.

  
 14 

									
			 (c)
		 Costs; Revenue. Upon written agreement by the Parties to pursue a Joint Cell Line and/or Joint Product,
the Primary Party, as designated by the Steering Committee, shall, unless otherwise agreed to in writing by the Parties:

					
							 (i)
		 bear all costs associated with or resulting from the development of a Joint Cell Line and/or Joint Product (collectively, the “Costs”), from the
conclusion of the Feasibility Work through commercialization, during which period the Primary Party and the Secondary Party shall split the Revenue generated from such Joint Cell Line and/or Joint Product in shares of [***]% and [***]%,
respectively; provided, however, that if the Secondary Party shares in the Costs associated with or resulting from the development of such Joint Cell Line and/or Joint Product in an amount of more than [***]%, then the Revenue shall be divided among
the Parties on a pro rata basis, and further provided, however, [***];

					
							 (ii)
		 bear all Costs associated with or resulting from the development of a Joint Cell Line and/or Joint Product, from the conclusion of the Feasibility Work to
before entering Phase I Clinical Trials, during which period the Primary Party and the Secondary Party shall split the Revenue generated from such Joint Cell Line and/or Joint Product in shares of [***]% and [***]%, respectively;

					
							 (iii)
		 bear all Costs associated with or resulting from the development of a Joint Cell Line and/or Joint Product, from the conclusion of the Feasibility Work to
before entering Phase II Clinical Trials, during which period the Primary Party and the Secondary Party shall split the Revenue generated from such Joint Cell Line and/or Joint Product in shares of [***]% and [***]%, respectively;

					
							 (iv)
		 bear all Costs associated with or resulting from the development of a Joint Cell Line and/or Joint Product, from the conclusion of the Feasibility Work to
before entering Phase III Clinical Trials, during which period the Primary Party and the Secondary Party shall split the Revenue generated from such Joint Cell Line and/or Joint Product in shares of [***]% and [***]%, respectively; or

					
							 (v)
		 bear all Costs associated with or resulting from the development of a Joint Cell Line and/or Joint Product, from the conclusion of the Feasibility Work to after
entering Phase III Clinical Trials but before commercialization, during which period the Primary Party and the Secondary Party shall split the Revenue generated from such Joint Cell Line and/or Joint Product in shares of [***]% and [***]%,
respectively.

			
					 For purposes of clarity, Costs include any costs associated with obtaining Third Party Rights pursuant to Section 3.4 hereto or otherwise which
the Primary Party reasonably deems necessary for its development, testing, Regulatory Approval, or commercialization of the Joint Cell Line and/or Joint Product.

  
 15 

					
					 The Primary Party for a Project will be entitled to exclusive access to any FTEs which are provided by a Third Party (such as a collaborator) for use in
connection with such Project.

		
	 2.5
		 Legal and Regulatory Compliance. In connection with the Program, each Party will (a) perform all of
its responsibilities and obligations in a timely, professional, and competent manner in compliance with all applicable laws and, to the extent applicable, GLPs, GCPS and GMPs, and (b) without limiting the generality of the foregoing, comply at
all times with the provisions of the Generic Drug Enforcement Act of 1992 and, upon request, certify in writing to the other Party that none of it, its employees, or any person providing services to it in connection with the activities
contemplated by this Agreement, have been debarred under the provisions of such Act.

 ARTICLE 3 

LICENSE GRANTS 
  

			
	 3.1
		 License to CONKWEST Rights. Subject to the terms and conditions of this Agreement, CONKWEST hereby grants to SRNE during the Term, a non-exclusive,
worldwide, royalty-free, non-transferable (except as provided in Section 13.2 hereof), non- sublicensable (except as provided in Section 3.3 hereof), right and license, under all of the CONKWEST Rights, to use the CONKWEST Rights solely for the
purpose of developing, testing, seeking Regulatory Approval for, and/or commercializing a Pre-Approved Joint Cell Line or Joint Product, including the right and license to make, have made, use, have used, sell, have sold, import, reproduce, modify,
publicly perform, publicly display, create derivatives of, and otherwise exploit and commercialize the CONKWEST Rights, but in any event solely for or in connection with a Pre-Approved Joint Cell Line or Joint Product, and solely in the manner and
to the extent permitted under the applicable Statement of Work(s) or as set forth in Section 2.4.

		
	 3.2
		 License to SRNE Rights. Subject to the terms and conditions of this Agreement, SRNE hereby grants to CONKWEST during the Term, a non-exclusive,
worldwide, royalty-free, non-transferable (except as provided in Section 13.2 hereof), non-sublicensable (except as provided in Section 3.3 hereof), right and license, under all of the SRNE Rights, to use the SRNE Rights solely for the purpose of
developing, testing, seeking Regulatory Approval for, and/or commercializing a Pre-Approved Joint Cell Line or Joint Product, including the right and license to make, have made, use, have used, sell, have sold, import, reproduce, modify, publicly
perform, publicly display, create derivatives of, and otherwise exploit and commercialize the SRNE Rights, but in any event solely for or in connection with a Pre-Approved Joint Cell Line or Joint Product, and solely in the manner and to the extent
permitted under the applicable Statement of Work(s) or in Section 2.4.

  
 16 

			
	 3.3
		 Sublicense Rights. The Primary Party in a given Project may, without the consent of the Secondary Party, sublicense any of the rights granted to it in
Section 3.1 or 3.2, as the case may be, to a Third Party with respect to the specific Joint Cell Line and/or Joint Product that the Primary Party is responsible for, in which case the Primary Party may only grant sublicenses to those Third
Parties that are performing contract services for and on behalf of the Primary Party in relation to one of the items listed in Section 2.4 hereto to the extent necessary to perform such contract services for such Project and consistent with the
Program. The Primary Party shall remain responsible for and liable for the conduct of its sublicensees hereunder. Further, the Primary Party may sublicense any of the rights granted to it in Section 3.1 or 3.2, as the case may be, to a
Third Party, as long as such Third Party has or assumes the same responsibilities as the Primary Party with respect to such Joint Cell Line and/or Joint Product provided, however, that the Secondary Party shall be provided with prior written notice
of and right to comment on such sublicense, such comment to be given fair consideration by the Primary Party.

		
	 3.4
		 Access to Third Party Rights. Nothing in this Agreement will restrict or prohibit a Party from acquiring or obtaining a license to any Intellectual
Property Rights of a Third Party (“Third Party Rights”), nor from using any Third Party Rights in the exercise of its rights and obligations under this Agreement. Any and all costs associated with Third Party Rights which are necessary or
reasonably useful for either Party to fulfill its obligations in furtherance of one or more Projects making up the Program without violating, misappropriating or infringing on any such Third Party Rights, shall be shared by the Parties at the pro
rata share set forth in Section 2.4(c) (including, without limitation, up-front payments, milestone payments, and royalties). The Party obtaining such Third Party Rights shall be required to obtain the right to, and shall, sublicense such Third
Party Rights to the other Party. Notwithstanding anything to the contrary in this Section 3.4, in the event the Secondary Party desires to obtain any Third Party Rights that will be subject to the cost sharing provision set forth in Section 2.4(c),
then: (i) the Secondary Party shall give the Primary Party written notice at least ten (10) business days prior to the date in which the Secondary Party acquires or licenses such Third Party Rights and provide the Primary Party with a copy of the
relevant acquisition or license agreement and any other information reasonably requested by the Primary Party with respect to such Third Party Rights, including the total cost to acquire or license such Third Party Rights, and (ii) the Primary Party
shall be entitled to terminate the Project prior to the date the Secondary Party’s acquires or licenses the applicable Third Party Rights, in which event, should the Secondary Party acquire or license the applicable Third Party Rights, the
Secondary Party shall be deemed to have exercised its option under Article 4 and be deemed the Primary Party with respect to the Project, including with respect to cost sharing.

		
	 3.5
		 Trademark License. Subject to the terms and conditions of this Agreement, each Party hereby grants to the other Party during the Term, a non-exclusive,
worldwide, royalty-free, non-transferable (except as provided in Section 13.2 hereof), non-sublicensable limited license to use the trademarks, service marks, and logos of the granting Party solely in connection with the licensed Party’s
performance of its rights and obligations under a given Project. Sample uses by the licensed Party of the trademarks, service marks, and logos of the granting Party will be provided to the granting Party upon request for review and approval by the
granting Party. The licensed Party will immediately cease

  
 17 

			
			 any usage of a trademark, service mark, or logo of the granting Party at any time upon the request of the granting Party if the licensed Party’s use is
damaging or otherwise harming the granting Party or the value or goodwill of such trademark, service mark, or logo. It is understood and agreed that the granting Party shall retain all right, title and interest in and to its trademarks, service
marks, and logos, and all benefits (including, without limitation, goodwill) accruing from a licensed Party’s use of such trademarks, service marks, and logos will automatically vest in and inure to the benefit of the granting
Party.

 ARTICLE 4 

OPTIONS 
  

			
	 4.1
		 Option to CONKWEST. To the extent that SRNE is the Primary Party with respect to any Joint Product as set forth in Section 2.4 hereto, in the event
that SRNE is unable to, or opts not to, undertake to perform or execute any or all of the responsibilities of the Primary Party set forth in Section 2.4 hereto and any Statements of Work detailing such responsibilities, SRNE hereby grants
CONKWEST an exclusive option to undertake to perform or execute such responsibilities of the Primary Party (the “CONKWEST Option”); provided, however, that such CONKWEST Option is subject to Section 4.4 hereto. For purposes of
clarity, the CONKWEST Option provides CONKWEST with the option, at its discretion, but not the obligation, to undertake to perform or execute any or all of the responsibilities of the Primary Party. The period of the CONKWEST Option commences on the
Effective Date hereof and continues for ninety (90) days from SRNE’s written notification to CONKWEST of its inability or option not to undertake to perform or execute such responsibility(ies); provided, however, that if CONKWEST does not
exercise the CONKWEST Option within such period of time, then the Parties may enter into an agreement with a Third Party for the performance or execution of such responsibilities on terms as are mutually negotiated and agreed to by the Parties, such
negotiation and agreement not be unreasonably withheld or delayed.

		
	 4.2
		 Option to SRNE. To the extent that CONKWEST is the Primary Party with respect to any Joint Product as set forth in Section 2.4 hereto, in the event
that CONKWEST is unable to, or opts not to, undertake to perform or execute any or all of the responsibilities of the Primary Party set forth in Section 2.4 hereto and any Statements of Work detailing such responsibilities, CONKWEST hereby
grants SRNE an exclusive option to undertake to perform or execute such responsibilities of the Primary Party (the “SRNE Option”); provided, however, that such CONKWEST Option is subject to Section 4.4 hereto. For purposes of clarity,
the SRNE Option provides SRNE with the option, at its discretion, but not the obligation, to undertake to perform or execute any or all of the responsibilities of the Primary Party. The period of the SRNE Option commences on the Effective Date
hereof and continues for ninety (90) days from CONKWEST’s written notification to SRNE of its inability or option not to undertake to perform or execute such responsibility(ies); provided, however, that if SRNE does not exercise the SRNE
Option within such period of time, then the Parties may enter into an agreement with a Third Party for the performance or execution of such responsibilities on terms as are mutually negotiated and agreed to by the Parties, such negotiation and
agreement not be unreasonably withheld or delayed.

  
 18 

			
	 4.3
		 Clarification. For purposes of clarity, in the event that one of the Options set forth in this Article 4 is not exercised, any use or
commercialization of a Joint Product by a Third Party requires the express written consent of both Parties.

		
	 4.4
		 Statement of Work; Separation. In the event that one Party exercises its respective Option granted in Section 4.1 or 4.2 hereto, as the case
may be, the Parties hereby agree that the Steering Committee shall prepare, and the Parties shall reasonably negotiate, a Statement of Work that specifically defines such Party’s responsibilities, including financial responsibilities, as the
new Primary Party and the other Party’s responsibilities, including financial responsibilities, as the new Secondary Party, such Statement of Work requiring unanimous written approval by the Steering Committee and, to the extent the Statement
of Work details financial obligations, of the CEO of each Party. If the Parties cannot agree on the terms of such Statement of Work, then the Parties hereby agree to reasonably negotiate a separation agreement between the Parties with respect to
such Project. For purposes of clarity, the exercise of a Party’s Option (or the decision not to exercise such Option) in accordance with the terms of this Article 4 with respect to a specific Project does not affect any rights of the
Parties with respect to other Projects that are part of the Program, or with respect to the Program itself.

 ARTICLE 5 

REPORTS 
  

			
	 5.1
		 Progress Reports. For each Joint Product, quarterly written reports summarizing the progress with respect to such Joint Product (“Progress
Reports”) shall be submitted by the Primary Party to the Secondary Party.

		
	 5.2
		 Final Report. For each Joint Product, upon completion of any preclinical studies or Phase I-IV Clinical Trials a written report summarizing the data and
results thereof (“Final Report”) shall be submitted by the Primary Party to the Secondary Party within three (3) months of completion of such studies or Clinical Trials.

		
	 5.3
		 Books and Records. For each Joint Product, each Party shall establish and maintain true and complete books of account, records, royalty statements,
license fees, invoices, and other data containing all particulars reasonably necessary for an independent determination of the amounts payable by each of the Parties under this Agreement (“Records”). The Records for each elapsed calendar
year during the Term of this Agreement shall be maintained for four (4) years after the end of such year. As to the Records of each Party, the other Party, its accountants, financial officers, attorneys, and outside Certified Public Accountants as
chosen by such other Party, shall have the right, during normal business hours and on thirty (30) days prior written notice, not more than once per calendar year, to audit, inspect, copy, and make extracts from all Records to the extent
necessary, and for the sole purpose of, verifying the accuracy of any payments made and statements furnished to such other Party. In the event any examination of the Records of one Party by the other Party discloses an underpayment to such other
Party: (i) the other Party shall provide written notice to the Party describing the findings; and (ii) the Party shall, within thirty (30) days of receipt of such written notice, pay to the other Party any undisputed

  
 19 

			
			 amount of any underpayment, plus all reasonable costs of audit and collection incurred by such other Party. All information obtained by the other Party as a
result of the activities performed under this Section 5.3 will be considered Confidential Information of the Party.

 ARTICLE 6 

INTELLECTUAL PROPERTY 
  

									
	 6.1
		 Existing Rights. SRNE acknowledges that CONKWEST owns all rights, title, and interest in and to the
CONKWEST Existing Rights and that, except as expressly set forth in Section 3.1 hereto, SRNE shall have no rights to CONKWEST Existing Rights. CONKWEST acknowledges that SRNE owns all rights, title, and interest in and to the SRNE Existing
Rights and that, except as expressly set forth in Section 3.2 hereto, CONKWEST shall have no rights to SRNE Existing Rights.

		
	 6.2
		 Ownership of Joint Product Rights; Patent Prosecution and Maintenance.

			
			 (a)
		 Ownership and Inventorship. CONKWEST and SRNE agree that ownership and inventorship with respect to all
Developed Intellectual Property Rights shall be determined according to US laws. Notwithstanding such ownership and inventorship, the Parties own an undivided interest in and to all rights, title, and interest in and to the Joint Product Rights as
set forth in Section 6.2(c) below.

			
			 (b)
		 Disclosure of Intellectual Property. Each Party agrees to promptly disclose information and Know-How
resulting from performance of a Project to the other Party on a confidential basis for evaluation.

			
			 (c)
		 Ownership of Joint Product Rights. The Parties agree that they own an undivided interest in and to all
rights, title, and interest in and to the Joint Product Rights (which, for clarity, excludes any CONKWEST Existing Rights and/or any SRNE Existing Rights incorporated into a Joint Product or Joint Cell Line, and any other Developed Intellectual
Property Rights which are not Joint Product Rights). To the extent any Joint Product Rights are or would, as a matter of law, be solely owned by one Party, such Party hereby irrevocably and unconditionally assigns a joint ownership interest in and
to such Joint Product Rights to the other Party. Each Party shall execute and deliver (and shall cause its employees and consultants to execute and deliver) all assignments and other documents necessary to assign the Joint Product Rights to the
Parties. Neither Party may make, have made, use, have used, sell, have sold, import, export, reproduce, display, transmit, modify, create derivative works of, sublicense, commercialize, and otherwise exploit in any manner the Joint Product Rights
without the prior written consent of the other Party other than as set forth in Section 2.4.

			
			 (d)
		 Filing and Prosecution of Project Patent Applications.

					
							 (i)
		 The Steering Committee shall determine in which countries any patent applications related to any Joint Product Rights shall be filed, prosecuted, and
maintained, including corresponding PCT

  
 20 

									
									 applications and national phase entry applications, and any and all patent applications, prosecution, issue and maintenance fees related to any divisional,
substitute, reissue, continuation, or extension patents that are based thereon (the “Joint Patents”). Unless otherwise agreed in writing, the Primary Party shall pay for any and all fees and costs resulting from drafting, filing,
prosecuting, or maintaining such Joint Patents and shall keep the Steering Committee updated on the status of such Joint Patents.

					
							 (ii)
		 In the event that the Steering Committee decides not to file a Joint Patent, or decides not to prosecute or maintain any such Joint Patent, then either Party
shall have the right to file, prosecute, or maintain such Joint Patent, in which case such Party shall bear all costs and expenses related thereto, including reimbursing the other Party for any costs and expenses paid by such other Party for
drafting, filing, prosecuting and/or maintaining such Joint Patent(s).

					
							 (iii)
		 The Parties shall reasonably cooperate with each other in preparing and filing all appropriate documentation in connection with any Joint Patents.

					
							 (iv)
		 For purposes of clarity, the terms of Section 2.4 hereto apply to rights granted in this Section 6.

		
	 6.3
		 Infringement by Third Parties.

			
			 (a)
		 Notice. If any of the CONKWEST Rights, SRNE Rights, or Joint Product Rights are infringed and/or
misappropriated by a Third Party, the Party first having knowledge of such infringement and/or misappropriation shall promptly notify the other Party in writing. The notice shall set forth the facts of such infringement and/or misappropriation in
reasonable detail.

			
			 (b)
		 Litigation of Infringement Actions.

					
							 (i)
		 Infringement Actions; CONKWEST Rights. CONKWEST shall have the sole and exclusive right, but not the obligation, to institute, litigate and control any
claim, action or proceeding with respect to any infringement and/or misappropriation by a Third Party (an “Infringement Action”) of any of the CONKWEST Rights, by counsel of its own choice, in which case SRNE shall reasonably cooperate
with CONKWEST at CONKWEST’s request and expense in the litigation of such Infringement Action, provided, however, that SRNE shall not be obligated to join in any such Infringement Action. CONKWEST shall be entitled to make all decisions with
respect to control of litigation, settlement, consent judgment or other voluntary final disposition of an

  
 21 

									
									 Infringement Action regarding the CONKWEST Rights, provided that CONKWEST shall have no right or authority to bind SRNE with respect to any such matters without
SRNE’s express prior written consent.

					
							 (ii)
		 Infringement Actions; SRNE Rights. SRNE shall have the sole and exclusive right, but not the obligation, to institute, litigate and control any
Infringement Action of the SRNE Rights, by counsel of its own choice, in which case CONKWEST shall reasonably cooperate with SRNE at SRNE’s request and expense in the litigation of such Infringement Action, provided, however, that CONKWEST
shall not be obligated to join in any such Infringement Action. SRNE shall be entitled to make all decisions with respect to control of litigation, settlement, consent judgment or other voluntary final disposition of an Infringement Action regarding
the SRNE Rights, provided that SRNE shall have no right or authority to bind CONKWEST with respect to any such matters without CONKWEST’s express prior written consent.

					
							 (iii)
		 Infringement Actions; Joint Product Rights. With respect to each Joint Product, the Primary Party shall have the initial right, but not the obligation,
to institute, litigate and control any Infringement Action with respect to any infringement and/or misappropriation of any of the Joint Product Rights pertaining to such Joint Product, by counsel of its own choice, in which case the Secondary Party
shall cooperate with the Primary Party in the litigation of such Infringement Action. If the Primary Party elects not to institute, litigate, or control such Infringement Action, then the Secondary Party shall have the right, but not the obligation,
to do so, in which case the Primary Party shall cooperate with the Secondary Party in the litigation of such Infringement Action. The Party that is not controlling such Infringement Action agrees to and hereby consents to be joined to such
Infringement Action at any time upon the request of the other Party. The party controlling such Infringement Action shall be responsible for all costs and expenses associated with such an Infringement Action. The Parties shall reasonably cooperate
in making all decisions with respect to control of litigation, settlement, consent judgment or other voluntary disposition of an Infringement Action regarding the Joint Product Rights, provided, however, that the Party controlling such Infringement
Action shall be entitled to make all final decisions with respect to the foregoing, but further provided that the Party controlling such Infringement Action shall have no right or authority to admit liability on behalf of the other Party without the
other Party’s express prior written consent. Any damages or other monetary awards recovered in such an Infringement Action shall be applied first to defray all of the costs and expenses incurred in

  
 22 

									
									 the Infringement Action. If any balance remains, then the Parties shall retain the balance according to their pro rata share as set forth in Section 2.4
hereto.

 ARTICLE 7 

REPRESENTATIONS AND WARRANTIES 
  

									
	 7.1
		 Mutual Representations. Each of the Parties represents and warrants to the other as follows:

			
			 (a)
		 Due Organization, Good Standing and Power. It is a corporation duly organized, validly existing and in good standing under the laws of its
jurisdiction of incorporation and has the power and authority to own, lease and operate its assets and to conduct the business now being conducted by it. It has all requisite power and authority to enter into this Agreement and to perform its
obligations hereunder.

			
			 (b)
		 Authorization and Validity of Agreements. The execution and delivery and the performance by it of this Agreement and the consummation by it
of the transactions contemplated hereby have been duly authorized and approved by all necessary corporate action on its part. This Agreement has been duly executed and delivered by it and constitutes its legal, valid and binding obligation
enforceable against it in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws relating to or affecting creditors’ rights generally and by general equity
principles.

			
			 (c)
		 Absence of Conflicts. The execution, delivery and performance of this Agreement, and the consummation by
it of the transactions contemplated hereby, do not and will not:

					
							 (i)
		 violate any applicable laws, regulations, orders, writs, injunctions or decrees of any applicable Government Authority;

					
							 (ii)
		 conflict with, or result in the breach of any provision of, its charter or bylaws;

					
							 (iii)
		 result in the creation of any lien or encumbrance of any nature upon any property being transferred or licensed pursuant hereto; or

					
							 (iv)
		 violate, conflict with, or result in the breach or termination of, or constitute a default under (or event which with notice, lapse of time or both would
constitute a default under) any permit, contract or agreement to which it is a party or by which its properties or businesses are bound.

  
 23 

					
			 (d)
		 Consents. No authorization, consent or approval of, or notice to or filing by such Party with, any governmental authority is required for the execution,
delivery and performance by such Party of this Agreement.

			
			 (e)
		 Employee Obligations. All of its employees, officers and consultants have legal obligations requiring, in the case of employees and officers, assignment
to it of all inventions made during the course of and as a result of their association with it and obligating all such individuals to maintain as confidential the confidential information of it, as well as the Confidential Information of a Party or
a Third Party which it may receive.

			
			 (f)
		 Compliance with Laws. It will obtain and maintain all necessary Regulatory Approvals for carrying out its work under a Project and, in carrying out its
work under a Project such work shall be carried out in compliance with (i) any applicable laws including, without limitation, federal, state, or local laws, regulations, or guidelines governing the work at the site where such work is being
conducted, and (ii) GLPs, GCPS and GMPs, to the extent applicable thereto.

			
			 (g)
		 It will comply at all times with the provisions of the Generic Drug Enforcement Act of 1992 and will, upon request, certify in writing to the other that
none of it, its employees, or any person providing services to it in connection with the activities contemplated by this Agreement have been debarred under the provisions of such Act.

			
			 (h)
		 Exclusivity. It will exclusively collaborate with the other Party with respect to the subject matter of this Agreement as set forth in Section
2.2.

		
	 7.2
		 CONKWEST’s Representations and Warranties. CONKWEST hereby represents and warrants to SRNE as
follows:

			
			 (a)
		 Existing Rights. CONKWEST exclusively owns all right, title, and interest in and to the CONKWEST Existing Rights, and to the knowledge of CONKWEST, the
CONKWEST Existing Rights, and the use thereof in accordance with the terms of this Agreement, do not and will not infringe upon, misappropriate, or otherwise violate any Third Party Rights.

			
			 (b)
		 No Infringement. No Person has asserted a claim, formal or informal, against CONKWEST that (i) challenges the validity of CONKWEST’s interest
in any component of the CONKWEST Existing Rights, (ii) alleges that CONKWEST’s use of any component of the CONKWEST Existing Rights infringes, misappropriates or violates any Third Party Rights, or (iii) seeks to enjoin or restrain
CONKWEST’s use of the CONKWEST Existing Rights in any manner that would interfere with the Program. To the best of CONKWEST’s knowledge, no Person has a meritorious basis for such a claim. To the best of CONKWEST’s knowledge, no
Person has infringed, misappropriated or violated CONKWEST’s rights with respect to any component of the CONKWEST Existing Rights.

  
 24 

					
			 (c)
		 Licenses. CONKWEST has the right to grant to SRNE the license to CONKWEST Rights granted pursuant to Section 3.1 hereto.

			
			 (d)
		 Exclusivity. CONKWEST shall not use Effector Cell Line(s), nor any modification, derivative, or improvement of the CONKWEST Cell Line or other Effector
Cell Line(s), with any TTM in any relationship with a Third Party, unless such rights to a TTM or Effector Cell Line are acquired or obtained pursuant to Section 3.4.

		
	 7.3
		 SRNE’s Representations and Warranties. SRNE hereby represents and warrants to CONKWEST as
follows:

			
			 (a)
		 Existing Rights. SRNE exclusively owns all right, title, and interest in and to the SRNE Existing Rights, and to the knowledge of SRNE, the SRNE Existing
Rights, and the use thereof in accordance with the terms of this Agreement, do not and will not infringe upon, misappropriate, or otherwise, violate any Third Party Rights.

			
			 (b)
		 No Infringement. No Person has asserted a claim, formal or informal, against SRNE that (i) challenges the validity of SRNE’s interest in any
component of the SRNE Existing Rights, (ii) alleges that SRNE’s use of any component of the SRNE Existing Rights infringes, misappropriates or violates any Third Party Rights, or (iii) seeks to enjoin or restrain SRNE’s use of
the SRNE Existing Rights in any manner that would interfere with the Program. To the best of SRNE’s knowledge, no Person has a meritorious basis for such a claim. To the best of SRNE’s knowledge, no Person has infringed, misappropriated or
violated SRNE’s rights with respect to any component of the SRNE Existing Rights.

			
			 (c)
		 Licenses. SRNE has the right to grant to CONKWEST the license to SRNE Rights granted pursuant to Section 3.2 hereto.

			
			 (d)
		 Exclusivity. SRNE shall not use any TTM in any relationship with a Third Party for any TTM-modified Effector Cell Line(s), or the Joint Cell Line(s) or
the Joint Product(s) thereof, unless such rights to a TTM or Effector Cell Line are acquired or obtained pursuant to Section 3.4.

 ARTICLE 8 

DISCLAIMER AND WAIVER 
  

			
	 8.1
		 Responsibility and Control. CONKWEST and SRNE shall each be solely responsible for the safety of its own employees, agents, licensees or sublicensees
with respect to efforts employed under the Program to the extent such safety concern was not caused by the other Party’s negligence or willful misconduct.

  
 25 

			
	 8.2
		 LIMITATION OF LIABILITY. EXCEPT WITH RESPECT TO A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT, AND TO THE MAXIMUM EXTENT PERMITTED BY
LAW, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, INCIDENTAL, OR PUNITIVE DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO LOSS OF ANTICIPATED PROFIT.
EXCEPT WITH RESPECT TO A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT, EACH PARTY’S TOTAL AGGREGATE LIABILITY IN CONNECTION WITH THIS AGREEMENT SHALL BE LIMITED TO ONE MILLION U.S. DOLLARS ($1,000,000).

		
	 8.3
		 Disclaimer. SRNE accepts the CONKWEST Rights with the knowledge that they are experimental in nature, may have hazardous properties, and hereby covenants
to comply with all applicable laws and regulations relating to the handling, use, storage and disposal of such CONKWEST Rights. CONKWEST accepts the SRNE Rights with the knowledge that they are experimental in nature, may have hazardous properties,
and hereby covenants to comply with all applicable laws and regulations relating to the handling, use, storage and disposal of such SRNE Rights. EXCEPT AS EXPRESSLY SET FORTH IN SECTION 7, THE CONKWEST CELL LINE AND THE SRNE TTMs ARE PROVIDED
“AS-IS”. EXCEPT AS EXPRESSLY SET FORTH IN SECTION 7, NEITHER PARTY MAKES ANY REPRESENTATIONS, AND EXTENDS NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE AND EACH PARTY HEREBY DISCLAIMS SAME. CONKWEST MAKES NO REPRESENTATION WITH RESPECT TO THE UTILITY, EFFICACY, NONTOXICITY, SAFETY OR APPROPRIATENESS OF USING THE CONKWEST RIGHTS. SRNE MAKES NO REPRESENTATION WITH RESPECT TO THE
UTILITY, EFFICACY, NONTOXICITY, SAFETY OR APPROPRIATENESS OF USING THE SRNE RIGHTS.

 ARTICLE 9 

CONFIDENTIALITY 
  

			
	 9.1
		 Obligations of the Parties. The terms of the Mutual Confidentiality Agreement apply to this Agreement and all materials, information, and Know-How of any
kind exchanged between the Parties hereunder.

  
 26 

 ARTICLE 10

INDEMNIFICATION AND INSURANCE 
  

			
	 10.1
		 Indemnity. Each Party (the “Indemnitor”) shall defend, indemnify and hold the other Party and its affiliates, and their officers, directors,
employees, agents, contractors, and customers (the “Indemnitee Parties”) harmless from and against all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) resulting from any claims, suits,
demands, actions and other proceedings by any Third Party to the extent resulting from (a) any recklessness or willful misconduct by or on behalf of the Indemnitor in the performance of its activities contemplate by this Agreement, (b) any breach
(or alleged breach) of any representation or warranty by the Indemnitor hereunder, or (c) any violation by the Indemnitor (or any of its employees or agents) of, or failure to adhere to, any applicable law, regulation or order in any country, in
each case other than those certain losses, liabilities, damages and expenses to the extent arising out of the recklessness or willful misconduct of the other party.

		
	 10.2
		 Indemnity Procedure. In the event an Indemnitee Party seeks indemnification hereunder, it shall inform the Indemnitor of a claim as soon as reasonably
practicable after it receives notice of the claim, shall permit the Indemnitor to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration) and shall cooperate as requested
(at the expense of the Indemnitor) in the defense of the claim. The indemnity obligations under this Section 10 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the
prior express written consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed.

		
	 10.3
		 Insurance. Each Party shall maintain commercial general liability insurance, including contractual liability insurance and products liability insurance
against claims regarding its activities contemplated by this Agreement, in such amounts as it customarily maintains for similar products and activities. Each Party shall maintain such insurance during the term of this Agreement and thereafter for so
long as it maintains insurance for itself covering such activities.

 ARTICLE 11 

PUBLICITY 
  

			
	 11.1
		 Disclosure of Agreement. Subject to the terms of the Mutual Confidentiality Agreement, neither Party may release any information to any Third Party
regarding the terms of this Agreement without the prior written consent of the other Party. Without limitation, this prohibition applies to press releases, educational and scientific conferences, investor updates, promotional materials, governmental
filings and discussions with public officials, the media, securities analysts and investors. However, this provision does not apply to any disclosures regarding this Agreement or related information made to (i) a Party’s professional advisors,
(ii) in connection with a Strategic Transaction, or (iii) Government Authority which may be required by law, including requests for a copy of this Agreement or related information by tax authorities. If any Party to this Agreement determines a
release of information regarding the terms of this Agreement is required by

  
 27 

			
			 law (including releases that may be required to be filed with the SEC), that Party will notify the other Party as soon as practicable and give as much detail as
possible in relation to the disclosure required. The Parties will then cooperate with respect to determining what information should actually be released.

		
	 11.2
		 Publications. During the term of this Agreement, each Party shall provide the other Party with an opportunity to review and comment upon any proposed
abstracts, manuscripts or proposed presentations that relate to a Project at least sixty (60) days prior to their intended submission for publication and agrees, upon request, not to submit such an abstract or manuscript for publication until
the Parties have reasonably agreed upon whether or not to file for patent protection for any material in such publication which the other Party believes to be patentable. Upon one Party’s reasonable request, the other Party shall delete from
its abstracts, manuscripts or presentations any reference to such Party’s Intellectual Property Rights to the extent such Party’s Intellectual Property Rights contain trade secrets and/or submitted but not yet published patent filings of
such Party.

		
	 11.3
		 Data. Notwithstanding anything to the contrary set forth in this Agreement or the Mutual Confidentiality Agreement, any and all data and technical
information pertaining to the Effector Cell Lines, SRNE TTMs, Joint Cell Lines, or Joint Products, or to any Phase I Clinical Trial, Phase II Clinical Trial, or Phase III Clinical Trial, may be shared by either Party, with: (i) any Third Party in
connection with Strategic Transaction or other strategic relationship between the disclosing Party and such Third Party, (ii) to the extent necessary to obtain any required Regulatory Approval, and (iii) to any Government Authority to the extent
required to comply with any applicable law or regulation; provided, however, that such Party sharing such data and technical information shall, to the extent permitted by applicable law, only share such data and technical information with a Third
Party under a confidentiality agreement no less protective than the terms and conditions of this Agreement, and further provided that the Party sharing such data and technical information with such Third Party shall be liable and responsible for the
conduct of such Third Party disclosees hereunder.

 ARTICLE 12 

TERM AND TERMINATION 
  

					
	 12.1
		 Term. The term of this Agreement (the “Term”) shall begin as of the Effective Date and shall (i)
expire upon completion of the Program, or (ii) continue until terminated in accordance with Article 2 or this Article 12.

		
	 12.2
		 Termination.

			
			 (a)
		 Dissolution or Insolvency Event. Either Party may terminate this Agreement effective immediately upon delivery of a Termination Notice if the other Party
(i) is dissolved under applicable corporate law and there is no successor to such Party’s business or assets relating to this Agreement, or (ii) becomes subject to an Insolvency Event.

  
 28 

					
			 (b)
		 Default. If either Party believes the other is in default of any of its material obligations under this Agreement, including failing to comply with a
Statement of Work, it may give notice of such default to the other Party, which Party shall have sixty (60) days in which to remedy such default. If such alleged default is not remedied in the time period set forth above, the Party alleging
default may terminate this Agreement immediately upon delivery to the defaulting Party of a Termination Notice. The non-defaulting Party’s right to terminate this Agreement shall not be construed as an exclusive remedy.

		
	 12.3
		 Wind Down Procedures. In the event of termination of a Project, the Program, or this Agreement, as the
case may be, pursuant to Section 12.1 or 12.2, the Project, Program, or Agreement shall be discontinued as of the Termination Date and the Parties shall in good faith commence the Wind Down Procedures promptly upon delivery of the Termination
Notice. As part of such Wind Down Procedures, (i) SRNE shall return to CONKWEST all CONKWEST Existing Rights, excluding CONKWEST Cell Lines embodied in a Joint Cell Line, and (ii) CONKWEST shall return to SRNE all SRNE Existing Rights,
excluding SRNE TTM-modified Joint Cell Lines. The Primary Party for the specific Joint Cell Lines and/or Joint Products that have been generated shall have sole discretion to either continue or discontinue the development of the specific Joint Cell
Lines and Joint Products. No new Project, however, shall be initiated by either Party.

		
	 12.4
		 Surviving Rights/Obligations. This Agreement shall continue until terminated in accordance with this
Article 12. Further, the provisions of Section 2.3(b)(iii), 2.4, and this 12.4, and of Articles 1 (Definitions), 6 (Intellectual Property), 7 (Representations and Warranties), 8 (Disclaimer and Waiver), 9 (Confidentiality), 10
(Indemnification and Insurance), 11 (Publicity), and 13 (Miscellaneous) of this Agreement, together with any provisions required for the interpretation or enforcement of any of the foregoing, shall survive the termination or expiration of this
Agreement. Termination of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of either Party prior to such termination.

 ARTICLE 13 

MISCELLANEOUS 
  

			
	 13.1
		 Agency. Neither Party is, nor shall be deemed to be, an employee, agent, partner or legal representative of the other Party for any purpose. Neither
Party shall have the right, power or authority to enter into any contracts in the name of, or on behalf of, the other Party, nor shall either Party have the right, power or authority to pledge the credit of the other Party in any way or hold itself
out as having the authority to do so.

		
	 13.2
		 Assignment. Neither Party may assign this Agreement or any of its rights, duties, or obligations hereunder without the prior written consent of the other
Party; provided, however, that either Party may assign this Agreement without the consent of the other

  
 29 

					
		 	 Party (a) to an affiliate of the assigning Party, or (b) to a Third Party in connection with a Strategic
Transaction. Any purported assignment in violation of the foregoing shall be void. Any permitted assignee shall assume all obligations under this Agreement.

		
	 13.3
	 	 Further Actions. Each Party agrees, subsequent to the execution and delivery of this Agreement and without
any additional consideration, to execute, acknowledge and deliver such further documents and instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

		
	 13.4
	 	 Force Majeure. If any Party is impeded in fulfilling its undertakings in accordance with this Agreement by
labor conflict, unforeseen acts of nature, including but not limited to flood, fire, storm etc., accident, war, mobilization or unforeseen military call-up of a large magnitude, requisition, confiscation, commandeering, legislative or judicial or
regulatory action, riot, insurrection, sabotage, terrorism, explosion, general shortage of transport, goods or energy and faults or delays in deliveries from sub-contractors or suppliers caused by any circumstances referred to in this
Section 13.4, the impediment shall be considered a Force Majeure and the Party shall be excused from liability for delays due to such reasons, provided always that it notifies the other Party without undue delay after such a circumstance has
occurred and provides the other Party with an estimate of the length of time during which it is probable that it will be unable to comply with said obligation(s). Where applicable, the Parties agree to set in place without delay any means to enable
them to prevent a rupture in the supply of any Product likely to have deleterious consequences for public health. In the event that the case of Force Majeure should last more than ninety (90) days, any Party shall have the option to suspend
application of this Agreement, which will resume automatically upon termination of the Force Majeure.

		
	 13.5
	 	 Notices. All notices, demands, waivers, instructions, consents and other communications hereunder shall be
in writing, shall be effective upon receipt, and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by
express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice):

	
	 If to CONKWEST, addressed to:

			
		 		  	 CONKWEST INCORPORATED

		 		  	 Attn: Barry J. Simon, M.D., Chief Executive Officer

		 		  	 2533 South Coast Highway 101, Suite 210,

		 		  	 Cardiff-By-The-Sea, CA 92007-2133

		 		  	 Telephone: (858) 633-0300

		 		  	 Fax: (858) 380-1999

	
	 With copy to:

			
		 		  	 PIETRAGALLO GORDON ALFANO BOSICK & RASPANTI, LLP

		 		  	 Attn: Alicia M. Passerin, Ph.D., Esq.

  
 30 

					
					 38th Floor, One Oxford Centre

					 Pittsburgh, PA 15219

					 Telephone: (412) 263-2000

					 Fax: (412) 261-0915

	
	 If to SRNE, addressed to:

			
					 Sorrento Therapeutics, Inc.

					 Attn: Henry Ji, Ph.D., President & Chief Executive Officer

					 6042 Cornerstone Court, Suite B

					 San Diego, CA 92121

					 Telephone: (858) 210-3701

					 Fax: (858) 210-3759

		
	 13.6
		 Amendment. No amendment, modification or supplement of any provision of this Agreement shall be valid or
effective unless made in writing and signed by a duly authorized officer of each Party.

		
	 13.7
		 Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its
agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party, which waiver shall be effective only with respect to the specific obligation and instance described
therein.

		
	 13.8
		 Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which
shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

		
	 13.9
		 Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of
no force or effect in construing or interpreting any of the provisions of this Agreement.

		
	 13.10
		 Governing Law. This Agreement shall be governed by and interpreted in accordance with the substantive laws
of the State of Delaware, without regard to its choice of law rules.

		
	 13.11
		 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to
be effective and valid under applicable law, but if any provision is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement. In such event, the Parties shall substitute for such invalid or prohibited provision a valid and enforceable provision consistent with the spirit and objective of such invalid or prohibited provision.

		
	 13.12
		 Entire Agreement of the Parties. This Agreement, including the Schedules hereto, and the Mutual
Confidentiality Agreement constitute and contain the complete, final and exclusive understanding and agreement of the Parties as to the matters covered herein and supersede any and all prior negotiations, correspondence, understandings and
agreements, whether oral or written, between the Parties respecting the subject matter hereof.

  
 31 

			
	 13.13
		 Jointly Prepared. This Agreement has been prepared jointly and shall not be strictly construed against either Party.

		
	 13.14
		 Third Party Rights. This Agreement is not intended to confer any benefits upon, or create any rights in favor of, any Person other than the Parties and,
where expressly provided, their affiliates.

		
	 13.15
		 Bankruptcy. The Parties agree that all rights and licenses granted under this Agreement are rights and licenses in “intellectual property”
within the scope of Section 101(35A) (or its successors) of Section 101 of the United States Bankruptcy Code, or its successors (collectively, the “Bankruptcy Code”) or any other similar law in any jurisdiction. Each Party, as a licensee
hereunder, shall have and may fully exercise all rights available to it under the Bankruptcy Code or any other similar law in any jurisdiction, including, without limitation, under Section 365(n) or its successors.

		
	 13.16
		 Board Seat. For as long as SRNE beneficially holds at least 250,000 shares of common stock of CONKWEST (subject to adjustment for stock splits, stock
dividends, recapitalizations and the like), SRNE shall have the right to appoint one individual to serve as a member of the Board of Directors of CONKWEST (the “Board Representative”) having observation rights; provided, however, that such
Board Representative shall receive full voting rights upon the closing of a private financing round for common stock of CONKWEST within six (6) months of the Effective Date of this Agreement, further provided that at least $10,000,000 of such gross
proceeds is from one or more SRNE Introduced Investors. Henry Ji, Ph.D., the current Chief Executive Officer of SRNE, shall be the initial Board Representative and appointed to the Board of Directors of CONKWEST effective as of the Effective
Date.

 [—remainder of page intentionally left blank—] 

  
 32 

 [SIGNATURE PAGE TO JOINT DEVELOPMENT AND LICENSE AGREEMENT] 

 
 IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement. 

 

									
	 CONKWEST INCORPORATED
				 SORRENTO THERAPEUTICS, INC.

					
	 By:
		 /s/ Barry Simon
				 By:
		 /s/ Henry Ji

					
	 Name:
		 Barry Simon
				 Name:
		 Henry Ji

					
	 Title:
		 President and CEO
				 Title:
		 President and CEO

 SCHEDULE 1 

SAMPLE STATEMENT OF WORK 

This Statement of Work (“SOW”) by and between CONKWEST INCORPORATED, a Delaware corporation with offices at
2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133 (“CONKWEST”), and SORRENTO THERAPEUTICS, INC., a Delaware corporation with offices at 6042 Cornerstone Ct. W., San Diego, Ca 92121 (“SRNE”) (each a
“Party” and together the “Parties”) is attached to and part of that certain Joint Development and License Agreement entered into between the Parties on December [•], 2014 (the “Agreement”). All of the terms
and conditions of the Agreement are incorporated herein by reference. To the extent of any conflict between this SOW and the Agreement, the terms of this SOW shall prevail. 

I. Joint Development. This SOW refers to the joint development of the following subject matter by the Parties as part of the Project
described in the Agreement: 
 [INSERT DESCRIPTION OF JOINT CELL LINE(S), JOINT PRODUCTS, OTHER JOINT MATERIALS OR SUBJECT MATTER TO BE
DEVELOPED UNDER THIS SOW] 
 II. Identification of the Primary and Secondary Parties; Responsibilities. For purposes of the Joint
Development described in Paragraph I of this SOW (the “Joint Development”), the Steering Committee has determined that
                     shall be the Primary Party and that
                     shall be the Secondary Party.  
  

	 	A.	 Responsibilities of the Primary Party. 

[INSERT LIST OF RESPONSIBILITIES, INCLUDING DELIVERABLES TO BE DELIVERED UNDER THIS SOW AND INCLUDE TIME LINE FOR COMPLETING SUCH
RESPONSIBILITIES/DELIVERING SUCH DELIVERABLES, ASSOCIATED LABOR RATES, ANY ANTICIPATED WORK BY THIRD PARTIES, ETC.] 
  

	 	B.	 Responsibilities of the Secondary Party. 

[INSERT LIST OF RESPONSIBILITIES, INCLUDING DELIVERABLES TO BE DELIVERED UNDER THIS SOW AND INCLUDE TIME LINE FOR COMPLETING SUCH
RESPONSIBILITIES/DELIVERING SUCH DELIVERABLES, ASSOCIATED LABOR RATES, ANY ANTICIPATED WORK BY THIRD PARTIES, ETC.] 
 III. Budget;
Allocation of Costs; Payment Terms. The budget attached hereto as Schedule A, which is a part of this SOW, has been agreed to by the Parties. Any and all Costs associated with or resulting from the Joint Development shall be allocated between
the Parties as follows: 
 [INSERT COST ALLOCATION OR INDICATE THAT THE COST ALLOCATION IS AS SET FORTH IN THE AGREEMENT]

 [INSERT PAYMENT TERMS] 

IV. TERM; TERMINATION. The term of this SOW shall commence on
             (“Effective Date” and shall continue for              (“Initial SOW Term”) unless
sooner terminated by either Party in accordance with the terms of the Agreement. This SOW shall automatically renew for additional          year terms at the same terms and conditions (each, a
“Renewal SOW Term”) upon the expiration of the Initial SOW Term and each Renewal SOW Term. The Initial SOW Term and the Renewal SOW Term, if any, shall be collectively referred to as the “SOW Term”. 

The Parties have caused this SOW to be executed by their respective duly authorized representatives. 

 

							
	 CONKWEST INCORPORATED
				 SORRENTO THERAPEUTICS, INC.

				
	
By:                            
                                         
     
				
By:                            
                                         
     
		
				
	
Print Name:                          
                                  
				
Print Name:                          
                                  
		
				
	
Title:                            
                                         
  
				
Title:                            
                                         
  
		
				
	
Date:                            
                                         
  
				
Date:                            
                                         
  
		

 THIS IS A SAMPLE SOW - DO NOT SIGN 

  
 2 

 SCHEDULE 2 

CONKWEST PATENTS 
 [***] 

 SCHEDULE 3 

SRNE PATENTS 
 [***] 

 SCHEDULE 4 

[INSERT EXECUTED MOU] 

  

 EXHIBIT A 

INVESTMENT AGREEMENT 

  

 EXHIBIT B 

REGISTRATION RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]